US Pat. No. 10,479,874

LATEX COMPOSITIONS AND ANTISTATIC ARTICLES MANUFACTURED THEREFROM

1. A process for making a static dissipative glove comprising:immersing a glove former in an aqueous coagulant solution to produce a coagulant coated former via a calcium salt;
immersing the coagulant coated former into a rubber dispersion to coat the coagulant coated former with a rubber;
washing the rubber coated on the coagulant coated former with water;
curing the rubber coated on the coagulant coated former in an oven;
chlorinating the rubber coated on the coagulant coated former by immersing the rubber coated on the coagulant coated former in an aqueous chlorine solution;
washing the rubber coated on the coagulant coated former with water;
drying the rubber coated on the coagulant coated former;
obtaining a glove by removing the rubber from the coagulant coated former; and
chlorinating the glove,
wherein the rubber dispersion comprises an additive, the additive comprises a precipitated calcium carbonate hydrate and an Azo based non-metallic organic pigment, the precipitated calcium carbonate hydrate is in the range of 5% to 30% of total composition by weight, the Azo based non-metallic organic pigment is in the range of 0.1% to 4% of total composition by weight, the aqueous chlorine solution comprises chlorine from 1,000 to 10,000 ppm, and the Azo based non-metallic organic pigment being orange color and having CAS number 3520-72-7.
US Pat. No. 10,481,158

COMPOSITIONS AND METHODS FOR SCREENING T CELLS WITH ANTIGENS FOR SPECIFIC POPULATIONS

California Institute of T...

1. An antigen complex, comprising:a nanoparticle sorting agent comprising:
a nanoparticle;
a polynucleotide detection tag having at least one coding region, the polynucleotide detection tag being conjugated to the nanoparticle; and
a first polynucleotide hybridization domain conjugated to the polynucleotide detection tag; and
a peptide-loaded streptavidin major histocompatability complex (MHC) tetramer, comprising:
a modified streptavidin protein;
four biotin-modified MHC proteins each independently conjugated to the modified streptavidin protein;
an antigen peptide bound to the biotin-modified MHC proteins; and
a second polynucleotide hybridization domain different from the first polynucleotide hybridization domain and conjugated to the modified streptavidin protein,
the nanoparticle sorting agent being linked to the peptide-loaded streptavidin MHC tetramer by hybridization of the first polynucleotide hybridization domain to the second polynucleotide hybridization domain.
US Pat. No. 10,477,822

SOYBEAN VARIETY 01069686

Monsanto Technology LLC, ...

1. A plant of soybean variety 01069686, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125858.
US Pat. No. 10,479,875

PROCESS FOR THE TREATMENT OF A COMPOSITION COMPRISING THERMOPLASTICS

SOLVAY SA, Brussels (BE)...

1. Process for the treatment of a composition comprising thermoplastics, the process comprising the steps ofa) introducing the composition comprising thermoplastics into a reactor under reduction of oxygen content of the atmosphere, wherein the oxygen content is reduced to below 10 vol % of gas phase,
b) heating the composition to a temperature in the range of 150° C. to 450° C. in the presence of a solvent, wherein the solvent has a boiling point of between 50° C. and 150° C. and wherein the amount of solvent is 0.1 kg to 10 kg per kg of thermoplastics, to obtain a drop in viscosity below 104 mPas of at least 50% by weight of the thermoplastics, based on the total content of the thermoplastics,
c) separating solid and/or gaseous fractions of the composition at the surface of the mixture and/or the bottom of the reactor, and
d) recovering liquefied thermoplastics from the reactor,
wherein the process steps a) to c) are conducted in one reactor.
US Pat. No. 10,481,159

IL-6 SIGNALING AND BREAST CANCER

CITY OF HOPE, Duarte, CA...

1. A method of detecting IL-6 activity in a breast cancer patient in remission, the method comprising the steps of:(i) obtaining a biological sample comprising CD4+ T cells from the breast cancer patient in remission;
(ii) contacting the biological sample with either: (a) an IL-6 pathway detection agent capable of binding an IL-6 pathway protein, wherein the IL-6 pathway protein is phosphorylated STAT1, phosphorylated STAT3, IL-6R?, or ADAM17, thereby forming a detectable complex; or (b) an IL-6 pathway probe capable of hybridizing an IL-6 pathway mRNA expression sequence, wherein the IL-6 pathway mRNA expression sequence is gp130; thereby forming a hybridization complex; and
(iii) detecting and/or quantifying either: (a) the detectable complex; or (b) the hybridization complex, respectively;thereby detecting IL-6 activity in the breast cancer patient in remission.
US Pat. No. 10,479,876

SULPHUR CONTAINING ADDITIVE FOR MAKING BITUMEN PAVING MIXTURES

Reliance Industries Limit...

1. A sulphur containing additive for bitumen paving mixtures, said sulphur containing additive comprising:a. sulphur;
b. a mixture of metal oxides; and
c. optionally, at least one metal sulphate,
wherein said mixture of metal oxides comprises calcium oxide in an amount in the range of 50 weight % to 60 weight %, silicon dioxide in an amount in the range of 25 weight % to 30 weight %, aluminium oxide in an amount in the range of 1 weight % to 2 weight %, and ferric oxide in an amount in the range of 8 weight % to 10 weight %.
US Pat. No. 10,481,160

COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER

KEIO UNIVERSITY, Minato-...

1. A method comprisingobtaining a first biological sample from a subject having cancer prior to administering an anti-cancer agent comprising oxaliplatin or a salt thereof and fluorouracil or a salt thereof;
administering the anti-cancer agent to the subject;
obtaining a second biological sample from the subject after the administering;
measuring a level of a substance, wherein the substance is cysteine-glutathione in the first and the second biological samples; and
continue administering the anti-cancer agent to the subject when the level of the substance is decreased in the second sample compared to the first sample or discontinuing the administration of the anti-cancer agent when the level of the substance is increased or unchanged in the second sample compared to the first sample.
US Pat. No. 10,479,878

ANTI-VIBRATION RUBBER COMPOSITION

SUMITOMO RIKO COMPANY LIM...

1. An anti-vibration rubber composition, comprising:(A) a diene-based rubber;
(B) a halogen-based flame retardant having a melting point of 150° C. or less; and
(C) aluminum hydroxide having an average particle diameter of 0.4 ?m or less,
wherein a blending amount of the halogen-based flame retardant (B) falls within a range of from 15 parts by weight to 60 parts by weight with respect to 100 parts by weight of the diene-based rubber (A), and a blending amount of the aluminum hydroxide (C) falls within a range of from 50 parts by weight to 150 parts by weight with respect to 100 parts by weight of the diene-based rubber (A).
US Pat. No. 10,481,162

PROTEIN SEQUENCING METHOD AND REAGENTS

The Governing Council of ...

1. A method of sequencing a polypeptide comprising:a. affixing the polypeptide to a substrate through a C?-terminal carboxyl group or a side chain functional group of the polypeptide;
b. contacting the polypeptide with a plurality of probes, wherein each probe comprises a fluorescent label and an affinity capture reagent that selectively binds to an N-terminal amino acid or a N-terminal amino acid derivative on the polypeptide;
c. optically detecting the fluorescent label of the probe bound to the polypeptide, thereby identifying the N-terminal amino acid of the polypeptide;
d. cleaving the N-terminal amino acid or N-terminal amino acid derivative of the polypeptide; and
e. repeating steps (b) to (d) to determine a sequence of successive N-terminal amino acids of at least a portion of the polypeptide.
US Pat. No. 10,481,165

ELEVATED CCL19 AFTER COMPLETION OF THERAPY FOR ACUTE LYME DISEASE IDENTIFIES PATIENTS AT RISK FOR DEVELOPMENT OF POST-TREATMENT LYME DISEASE SYNDROME WHO WILL BENEFIT FROM FURTHER ANTIBIOTIC THERAPY

The Johns Hopkins Univers...

1. A method for treating a patient likely to develop post-treatment Lyme disease syndrome (PTLDS) and who is currently undergoing a first course of antibiotic treatment for Lyme disease comprising the step of prescribing or administering a second course of antibiotic treatment to a patient who is determined to have an increased level of CCL19 as compared to a control after completing a first course of antibiotics for Lyme disease.
US Pat. No. 10,481,166

MICROPARTICLE FRACTIONATION

Singapore Health Services...

1. A method for selecting microparticles in a sample, the method comprising selecting microparticles by size; and one or both of:(a) selecting microparticles in the sample which comprise GM1 gangliosides; and
(b) selecting microparticles in the sample which comprise exposed phosphotidylserine.
US Pat. No. 10,479,883

COMPOSITIONS FOR AUTOMOTIVE INTERIOR PARTS

SABIC GLOBAL TECHNOLOGIES...

1. Composition comprising a heterophasic propylene copolymer and an ethylene polymer wherein the ethylene polymer has a density as measured according to ISO 1183-1 (2012), method A of ?940 kg/m3, the ethylene polymer has a multimodal molecular weight distribution and the ethylene polymer has a strain hardening modulus of ?5.0 MPa, the strain hardening modulus being measured according to ISO DIS 18488 (2014) using test specimens of 0.30 mm thickness.
US Pat. No. 10,481,167

METHODS FOR MEASURING CONCENTRATIONS OF BIOMOLECULES

C2N Diagnostics, Saint L...

1. A method of determining the absolute concentration of an amyloid-beta protein (A?), isoform, variant or digestion product thereof in a subject, comprising:(a) metabolically labeling the endogenous A? protein isoform, variant or digestion product thereof by administering at least one labeled moiety to the subject, wherein the at least one labeled moiety metabolically incorporates into the endogenous A? protein isoform, variant or digestion product thereof;
(b) contacting a biological sample obtained from the subject with a Quantitation Standard (QS) comprising a known concentration of a biomolecule labeled with two labeled moieties such that the labeled QS has a molecular weight that differs from the metabolically labeled endogenous A? protein isoform, variant or digestion product thereof, wherein the QS is an A? peptide, wherein the biological sample comprises a metabolically labeled fraction of the endogenous A? protein isoform, variant or digestion product thereof and an unlabeled fraction of the A? protein, isoform, variant or digestion product thereof;
(c) isolating the metabolically labeled, the unlabeled and the labeled QS forms of A? protein isoform, variant or digestion product thereof from the biological sample using a detergent to increase the labeled A?, unlabeled A? peptides and QS solubility;
(d) maintaining the labeled A?, unlabeled A? peptides and QS in a reduced state to increase said peptides detection;
(e) subjecting the labeled A?, unlabeled A? peptides and QS to mass spectroscopy analysis; and
(f) calculating the absolute concentration of the endogenous, metabolically labeled and unlabeled, A? protein isoform, variant or digestion product thereof using the known concentration of A? protein isoform, variant or digestion product in the labeled QS.
US Pat. No. 10,479,885

THERMOPLASTIC RESIN COMPOSITION AND ARTICLE PRODUCED THEREFROM

Lotte Advanced Materials ...

1. A thermoplastic resin composition comprising:about 10 wt % to about 30 wt % of a first rubber-modified vinyl graft copolymer obtained by grafting a monomer mixture comprising an aromatic vinyl monomer and a vinyl cyanide monomer to a diene rubber polymer;
about 1 wt % to about 15 wt % of a second rubber-modified vinyl graft copolymer obtained by grafting a monomer mixture comprising an aromatic vinyl monomer and a vinyl cyanide monomer to an acrylate rubber polymer;
about 10 wt % to about 40 wt % of a first aromatic vinyl-vinyl cyanide copolymer having a weight average molecular weight of about 250,000 g/mol to about 450,000 g/mol and including about 25 wt % to about 31 wt % of a repeat unit derived from a vinyl cyanide monomer;
about 20 wt % to about 60 wt % of a second aromatic vinyl-vinyl cyanide copolymer having a weight average molecular weight of about 70,000 g/mol to about 150,000 g/mol and including about 33 wt % to about 42 wt % of a repeat unit derived from a vinyl cyanide monomer; and
5 wt % to about 15 wt % of a third aromatic vinyl-vinyl cyanide copolymer having a weight average molecular weight of about 70,000 g/mol to about 150,000 g/mol and including about 25 wt % to about 31 wt % of a repeat unit derived from a vinyl cyanide monomer, each based on 100 wt % of the thermoplastic resin composition,
wherein the thermoplastic resin composition has a fracture strain ratio ?1/?0 of about 65% to about 90%, as measured in accordance with ASTM D543-06 using a 3.2 mm thick specimen, wherein ?1 is fracture strain measured when the specimen not exposed to a chemical reagent is subjected to tensile testing and ?0 is fracture strain measured when the specimen exposed to a chemical reagent is subjected to tensile testing, wherein tensile testing is conducted at a tensile rate of 5 mm/min in accordance with ASTM D638.
US Pat. No. 10,477,833

LOW DENSITY PET LITTERS AND METHODS OF MAKING SUCH PET LITTERS

1. A method of making a pet litter comprising:compacting a material comprising clay and expanded perlite fines to form a compacted material comprising expanded perlite fines, wherein the compacting is performed at a pressure from about 500 to about 1,300 psi;
breaking the compacted material comprising expanded perlite fines to form particles of the compacted material comprising expanded perlite fines;
separating the particles which have a size within a predetermined size range from a remainder of the particles;
drying the particles which have the size within the predetermined size range; and
using the dried particles as at least a portion of the pet litter, wherein the method does not contain activated carbon.
US Pat. No. 10,479,889

THERMOPLASTIC RESIN COMPOSITION, MOLDED ARTICLE MADE THEREFROM, AND METHOD OF PREPARING THE COMPOSITION

SAMSUNG ELECTRONICS CO., ...

1. A thermoplastic resin composition comprising:a polylactic acid;
a thermoplastic polymer having a lower glass transition temperature than the polylactic acid;
an inorganic nucleating agent; and
at least two reactive plasticizers comprising a modified vegetable oil,
wherein the thermoplastic resin composition comprises about 70% or more of the polylactic acid based on the total weight of the thermoplastic resin composition,
wherein the thermoplastic polymer comprises an ethylene vinyl acetate copolymer, which comprises about 60 wt % to about 75 wt % of an ethylene-based structural unit and about 25 wt % to about 40 wt % of a vinyl-acetate based structural unit.
US Pat. No. 10,479,890

OXYGEN SCAVENGING POLYESTER COMPOSITIONS FOR CONTAINERS

APG Polytech, LLC, Wilmi...

1. An oxygen scavenging composition for containers comprising:at least one polyester component,
a transition metal catalyst,
an oxygen scavenger, and
a vegetable oil comprising at least one molecule having a double allylic structure,wherein the at least one polyester component comprises at least one acid unit and at least one diol unit, the concentration of the double allylic structures of the vegetable oil in the composition is greater than 5.0 meq/kg of all of the polyester components, the oxygen scavenger is present in the composition in a traditionally inert amount, and the vegetable oil is present in the composition at a level greater than 0.3% by weight relative to the total weight of the polyester components, the transition metal catalyst and the vegetable oil.
US Pat. No. 10,479,898

COATING COMPOSITION FOR SUBSTRATES IMMERSED IN WATER

AKZO NOBEL COATINGS INTER...

1. A coating composition comprisinga) seawater-hydrolyzable groups covalently linked to an acrylic polymer, which seawater-hydrolyzable groups are capable of undergoing hydrolysis or ion-exchange when exposed to seawater, rendering the polymer partially soluble or dispersible in seawater, and
b) zwitterionic groups covalently linked to the acrylic polymer
wherein the molar ratio of the seawater-hydrolyzable groups a) to the zwitterionic groups b) is 0.1 or higher,
wherein the seawater hydrolyzable groups are selected from
the group consisting of non-metal salt groups, metal salt groups, silyl ester groups, and mixtures thereof, and
wherein the non-metal salt groups covalently linked to the acrylic polymer are
selected from the group consisting of quaternary and acid salts of dialkylaminoalkyl(meth)acrylates, quaternary and acid salts of dialkylaminoalkyl(meth)acrylamides, N,N-diallyldialkyl ammonium halide, (3-methacryloylamido)propyl trimethylammonium halide salt; (3-acryloylamido)propyl trimethylammonium halide salt; (3-methacryloylamido)propyl trimethylammonium sulfonate salt, (3-acryloylamido)propyl trimethylammonium sulfonate salt, (3-methacryloyl)propyl trimethylammonium sulfonate salt, (3-acryloyl)propyl trimethylammonium sulfonate salt, and
amine and phosphine salts of polymerizable unsaturated carboxylic and sulphonic acids
wherein the silyl ester groups covalently linked to the acrylic polymer are selected from the group consisting of triisopropylsilyl (meth)acrylate, triisobutylsilyl (meth)acrylate, triphenylsilyl (meth)acrylate, and t-butyldiphenylsilyl (meth)acrylate.
US Pat. No. 10,479,899

METHOD FOR PREPARING CATIONIC ELECTRODEPOSITION COATING COMPOSITION

NIPPON PAINT AUTOMOTIVE C...

1. A method for preparing a cationic electrodeposition coating composition, wherein the method comprises the steps of:preparing a resin emulsion (i) by respectively dissolving an aminated resin (A) and a blocked isocyanate curing agent (B) in organic solvents to prepare respective solutions, mixing the respective solutions to achieve a mixed solution, and then neutralizing the mixed solution with a neutralizing acid to obtain the resin emulsion (i) comprising the aminated resin (A) and the blocked isocyanate agent (B),
preparing a pigment dispersion paste comprising a bismuth mixture (C) obtained by mixing a bismuth compound (c1) and an organic acid (c2) in advance; a pigment dispersion resin (D); an amine-modified epoxy resin emulsion (ii) comprising an amine-modified epoxy resin (E); and a pigment (F), according to any one of the following methods of:
mixing the bismuth mixture (C) and the pigment dispersion resin (D), then the obtained mixture being mixed with the amine-modified epoxy resin emulsion (ii), and next, the pigment (F) being mixed in the obtained mixture;
mixing the bismuth mixture (C), the pigment dispersion resin (D) and the amine-modified epoxy resin emulsion (ii), and then the pigment (F) being mixed in the obtained mixture; or
mixing the bismuth mixture (C) and the amine-modified epoxy resin emulsion (ii), and then, the obtained mixture, the pigment dispersion resin (D) and the pigment (F) being mixed, and
mixing the resin emulsion (i) and the pigment dispersion paste to obtain the cationic electrodeposition coating composition, wherein
the pigment dispersion resin (D) has a hydroxyl value of 20 to 120 mg KOH/g, and
the amine-modified epoxy resin (E) has a primary amino group, a hydroxyl value of 150 to 650 mg KOH/g, and an amine value of 20 to 80 mg KOH/g.
US Pat. No. 10,479,133

MOLDING FILM AND MOLDING TRANSFER FOIL USING SAME

Toray Industries, Inc., ...

1. A molding film comprising mainly a cyclic olefin-based resin, whereinwhen an X surface represents one surface of the film and a Y surface represents another surface of the film, the X surface and the Y surface both have a surface glossiness of 50% or less, and
a ratio between thermal shrinkage in a transverse direction and thermal shrinkage in a machine direction at 80° C. satisfies ?2< the thermal shrinkage in the transverse direction/the thermal shrinkage in the machine direction
US Pat. No. 10,479,903

UV-CURABLE INKJET INK COMPOSITION

SHOWA ALUMINUM CAN CORPOR...

1. A UV-curable inkjet ink composition that contains a monofunctional monomer (A), a polyfunctional monomer (B), a photopolymerization initiator (C) and a colorant (D) and is cured by irradiation with ultraviolet light, whereina hydroxyl value of the UV-curable inkjet ink composition is in a range of not less than 1 mgKOH/g and not more than 100 mgKOH/g, and
the UV-curable inkjet ink composition forms, by inkjet printing, an ink layer provided between a curved outer peripheral surface of a can base made of a cylindrical metallic material and a covering layer made of an aqueous coating material.
US Pat. No. 10,479,906

USE OF FUNGAL PIGMENTS FROM WOOD-STAINING FUNGI AS COLORANTS IN WOOD FINISHES AND PAINTS

Oregon State University, ...

1. A composition comprising a fungal pigment suspended or solvated in an oil carrier, wherein the fungal pigment is an extracellular pigment from a fungi selected from the Chlorociboria genus, the Scytalidium genus, or any mixture thereof, and wherein the composition does not include an organic solvent.
US Pat. No. 10,479,907

VINYL ACETATE BINDERS IN AN ABOVE-CRITICAL PVC COATINGS COMPOSITION

Dow Global Technologies L...

1. A coating composition comprising an aqueous dispersion of polymer particles, pigment particles, and extender particles wherein the polymer particles comprise, in a single phase and based on the weight of the polymer particles, greater than 80 up to 99.8 weight percent structural units of vinyl acetate; from 0.1 to 6 weight percent structural units of a phosphorus-containing acid monomer or a salt thereof; and from 0.1 to 2 weight percent structural units of a sulfur-containing acid monomer or a salt thereof; wherein the polymer particles have a particle size by dynamic light scattering of from greater than 350 nm to 500 nm, and wherein the coating composition has an above-critical pigment volume concentration, as determined by reflectance, wherein the phosphorus-containing acid monomer or salt thereof is a dihydrogen phosphate esters of an alcohol in which the alcohol contains or is substituted with a polymerizable vinyl or olefinic group.
US Pat. No. 10,477,859

PLANT EMBRYO STORAGE AND MANIPULATION

PIONEER HI-BRED INTERNATI...

1. A method for performing molecular analysis of one or more plant embryos comprising agitating the plant embryos to remove cellular material for molecular analysis, storing the one or more plant embryos in an aqueous solution surrounded by a matrix of at least two oils, wherein one of the at least two oils is more dense than the aqueous solution and one of the at least two oils is less dense than the aqueous solution, obtaining genetic material from the cellular material removed from the plant embryos, and performing molecular analysis of the genetic material.
US Pat. No. 10,479,913

SILICONE COMPOSITION AND A PRESSURE SENSITIVE ADHESIVE FILM HAVING A PRESSURE SENSITIVE ADHESIVE LAYER MADE FROM THE COMPOSITION

Dow Silicones Corporation...

1. A silicone composition comprising:(A) a diorganopolysiloxane having at least two alkenyl groups in a molecule and having a viscosity at 25° C. of from 10,000 to 1,000,000 mPa·s, in an amount of from 60 to 80 mass % based on the mass of the composition;
(B) a diorganopolysiloxane having at least one alkenyl group in a molecule, and being raw and rubber-like at 25° C. or having a viscosity at 25° C. of more than 1,000,000 mPa·s, in an amount of from greater than 0 to 10 mass % based on the mass of the composition;
(C) an organopolysiloxane resin represented by the following average unit formula:
(R13SiO1/2)x(SiO4/2)1.0
wherein each R1 represents a halogen-substituted or un-substituted monovalent hydrocarbon group free from an alkenyl group and x is a number from 0.5 to 1.0, in an amount of from 0.5 to 20 mass % based on the mass of the composition;
(D) an organohydrogenpolysiloxane having at least two silicon-bonded hydrogen atoms in a molecule, in a quantity that provides from 0.1 to 10 moles of the silicon-bonded hydrogen atoms in this component per 1 mole of the total alkenyl groups in the composition;
(E) silica fine powder in an amount of from 0.5 to 5 mass % based on the mass of the composition; and
(F) a hydrosilylation catalyst in a quantity that accelerates hydrosilylation of the composition.
US Pat. No. 10,482,991

SYSTEMS AND METHODS FOR SAMPLING AND ANALYSIS OF POLYMER CONFORMATIONAL DYNAMICS

ZYMEWORKS INC., Vancouve...

1. A method of sampling and analysis of protein conformational dynamics by searching the conformation space of a protein to determine whether a three-dimensional conformation of the protein can co-engage each antigen in a plurality of target antigens, the protein comprising a first plurality of residues, the method comprising:at a computer system having one or more processors and memory storing one or more programs to be executed by the one or more processors:
(A) obtaining from the memory an initial set of three-dimensional coordinates {x1A_init, . . . , xNA_init, x1B_init, . . . , xMB_init, x1C_init, . . . , xPC_init, . . . } for the protein, wherein
the polymer comprises a plurality of domains,
each respective xiA in {x1A_init, . . . , xNA_init, x1B_init, . . . , xMB_init, x1C_init, . . . , xPC_init, . . . } is a three dimensional coordinate for an atom in a first domain in the plurality of domains,
each respective xiB in {x1A_init, . . . , xNA_init, x1B_init, . . . , xMB_init, x1C_init, . . . , xPC_init, . . . } is a three dimensional coordinate for an atom in a second domain in the plurality of domains, and
each respective xiC in {x1A_init, . . . , xNA_init, x1B_init, . . . , xMB_init, x1C_init, . . . , xPC_init, . . . } is a three dimensional coordinate for an atom in a first hinge of the protein, wherein the first hinge comprises a second plurality of residues that is a subset of the first plurality of residues, wherein the protein is characterized by an ability for the first and second domain to pivot with respect to each other about the first hinge;
(B) altering the initial set of three-dimensional coordinates of the protein by pivoting the first domain with respect to the second domain about the first hinge thereby obtaining an altered set of three-dimensional coordinates {x1A_alt, . . . , xNA_alt, x1B_alt, . . . , xMB_alt, x1C_alt, . . . , xPC_alt, . . . } for the protein, wherein
all atoms within the first domain are held fixed with respect to each other during the altering, and
all atoms within the second domain are held fixed with respect to each other during the altering;
(C) scoring, using a scoring module, a calculated potential energy of the altered set of coordinates versus a calculated potential energy of the initial three-dimensional coordinates for the protein with a Metropolis criterion, wherein, when the Metropolis criterion is satisfied, the altered set of three-dimensional coordinates is accepted as the initial set of three-dimensional coordinates;
(D) performing additional instances of the altering (B) and the scoring (C) until an energy of the altered set of three-dimensional coordinates {x1A_alt, . . . , xNA_alt, x1B_alt, . . . , xMB_alt,, x1C_alt, . . . xPC_alt, . . . } satisfy the Metropolis criterion; and
(E) evaluating whether the altered set of three-dimensional coordinates {x1A_alt, . . . , xNA_alt , x1B_alt, . . . , xMB_alt, x1C_alt, . . . , xPC_alt, . . . } can co-engage each antigen in the plurality of target antigens by docking the altered set three-dimensional coordinates to a model of the plurality of antigens.
US Pat. No. 10,482,993

ANALYZING COPY NUMBER VARIATION IN THE DETECTION OF CANCER

Verinata Health, Inc., S...

1. A method, implemented using a computer system comprising one or more processors and system memory, for identifying the presence of a cancer and/or an increased risk of a cancer in a mammal, said method comprising:(a) providing, to the computer system, at least 10,000 sequence reads of nucleic acids in a test sample from said mammal, wherein said test sample comprises both nucleic acids from cancerous or precancerous cells and nucleic acids from constitutive cells, wherein the sequence reads are provided in an electronic format;
(b) aligning, by the one or more processors, the at least 10,000 sequence reads to one or more reference sequences using a computing apparatus and thereby providing sequence tags corresponding to the sequence reads;
(c) identifying, by the one or more processors, a number of sequence tags from the nucleic acids for one or more sequences of interest amplifications of which or deletions of which are known to be associated with cancers, wherein said sequences of interest are selected from chromosomes 1-22, X, and Y and segments thereof and identifying, by the one or more processors, a number of sequence tags for at least one normalizing sequence for each of the one or more sequences of interest;
(d) calculating, by the one or more processors and using said number of sequence tags identified for each of said one or more sequences of interest and said number of sequence tags identified for each said normalizing sequence, a single sequence dose for each of said one or more sequences of interest,
wherein the at least one normalizing sequence is a sequence that yields sequence doses for the sequence of interest having: (a) the smallest variability among unaffected samples, (b) the greatest differentiability between affected and unaffected samples, (c) the smallest variability and the greatest differentiability, or (d) an optimal combination of small variability and large differentiability;
(e) evaluating said single sequence dose for each of said one or more sequences of interest, and thereby detecting aneuploidies or copy number variations in said sample; and
(f) determining the presence of a cancer and/or an increased risk of a cancer based on the detected aneuploidies or copy number variations.
US Pat. No. 10,484,535

METHOD AND SYSTEM FOR TEXT ENABLEMENT OF LANDLINE TELEPHONE NUMBER WITH THREAD AND GROUP CHAT ENABLEMENT

1. A system for converting a telephone number not provisioned for receipt and output of Short Messaging Service (SMS) text messages into an SMS-to-electronic mail conversion enabled telephone number, wherein the system is configured to:assign a carrier's Service Profile IDentifier (SPID) to the telephone number not provisioned for receipt and output of SMS text messages;
receive an SMS text message from an SMS text message sender, wherein the SMS text message is addressed to be received at the telephone number not provisioned for receipt and output of SMS text messages and the SMS text message is routed to the carrier's SMS gateway based on the carrier's assigned SPID;
include content of the SMS text message in an electronic mail message to a user associated with that telephone number not provisioned for receipt and output of SMS text messages, and sending the electronic mail message to the user at a computer and/or mobile device associated with the user, wherein the content of the SMS text message is included in the electronic mail message sent to the user automatically in response to receiving the SMS text message addressed to the telephone number not provisioned for receipt and output of SMS text messages;
receive a user's electronic mail message response to the electronic mail message including content of the SMS text message, wherein content of the electronic mail message response is formulated by the user on the computer or the mobile device and sent from the computer or the mobile device; and
include the content of the electronic mail message response in a response SMS text message sent to a telephone number of the SMS text message sender,
wherein the response SMS text message indicates the telephone number not provisioned for receipt and output of SMS text messages as the telephone number sending the response SMS text message, and
wherein the content of the SMS text message, the content of the response SMS text message and any subsequent SMS text messages and response SMS text messages sent between the SMS text message sender and the user are combined in an electronic mail message sent to the user's computer device or mobile phone,
whereby the user is made aware of SMS text messages erroneously sent to their telephone number that is not provisioned for receipt and output of SMS text messages.
US Pat. No. 10,479,916

LATENT TWO-PART POLYURETHANE ADHESIVES CURABLE WITH INFRARED RADIATION

DOW GLOBAL TECHNOLOGIES L...

1. A composition comprising a polyol component and an isocyanate component, wherein:a) the polyol component includes;
i) one or more polyols having a hydroxyl equivalent weight of 400 to 2000 and a nominal hydroxyl functionality of 2 to 4;
ii) one or more aliphatic diol chain extenders; and
iii) one or more latent room temperature organometallic catalysts;
b) the polyisocyanate component includes:iv) one or more polyisocyanate compounds;wherein the polyisocyanate component includes isocyanate groups and the polyol component isocyanate-reactive groups wherein a ratio of a number of the isocyanate groups in the polyisocyanate component to a number of the isocyanate-reactive groups in the polyol component is about 1.0 to about 1.8; and v) one or more carboxylic acid-blocked cyclic amidine compounds and vi) one or more phenol-blocked cyclic amidine compounds are located in the polyol component or the isocyanate component and the composition is useful as a two-component polyurethane adhesive composition.
US Pat. No. 10,478,638

RECOMBINANT SELF-ASSEMBLING PROTEIN COMPRISING TARGET-ORIENTED PEPTIDE AND USE THEREOF

Korea University Research...

1. A recombinant self-assembled protein, comprising a target-oriented peptide fused to a self-assembled protein, wherein the target-oriented peptide is a cancer-targeting peptide ligand.
US Pat. No. 10,482,997

METHOD FOR DETERMINING THREE-DIMENSIONAL STRUCTURES OF DYNAMIC MOLECULES

Conformetrix Limited, Ma...

1. A method for generating an ensemble of discrete molecular structures representing a range of three-dimensional shapes of a solvated molecule, the molecule comprising a plurality of bonds each having an associated mean dihedral angle, wherein at least one bond is a rotatable bond having an associated distribution of dihedral angles, the method comprising:receiving a set of internal coordinates of the molecule, said internal coordinates comprising a predefined mean dihedral angle for each bond; then
assigning a probability distribution function to each bond, the probability distribution function comprising a predefined variability of the dihedral angle for said bond with respect to said predefined mean dihedral angle, the probability distribution function independent of experimental data for the solvated molecule; and then
generating an ensemble of structures by implementing the set of internal coordinates and the assigned probability distribution functions by varying said dihedral angle for each bond according to said predefined dihedral angle variability; and then
analyzing the ensemble of structures as a group,
wherein all of the preceding steps are performed on a computer, and
wherein the predefined variability of the dihedral angle for a rotatable bond is non-zero and corresponds to the associated distribution of dihedral angles.
US Pat. No. 10,477,869

NACL SUBSTITUTE AGENT

LESAFFRE ET COMPAGNIE, P...

1. A method for reducing the amount of NaCl in breadmaking, comprising a step of totally or partially replacing NaCl with a NaCl substitute, said NaCl substitute consisting of deactivated yeast and NaCl, and optionally a cereal extract and/or a breadmaking improver selected from the group consisting of ascorbic acid, emulsifiers, stabilizing-thickening agents, enzymes and mixtures thereof, wherein the NaCl/deactivated yeast ratio is between 1 and 5.7.
US Pat. No. 10,478,384

DENTAL COMPOSITION

Zimmer Dental, Inc., Car...

1. A dental composition for a dental implant insertable into an implant site, comprising:a reaction product of a reaction mixture comprising:
a first mixture comprising:
a ceramic based biomaterial including hydroxyapatite,
a diluent comprising a cross-linking agent, and
a first initiator, and
a second mixture comprising:
mineral trioxide aggregate reacts with moisture at the implant site to form a solid scaffold on the dental implant,
a phosphoric acid monomer reacts with the ceramic based biomaterial and the mineral trioxide aggregate to bond the ceramic based biomaterial to the solid scaffold of mineral trioxide aggregate, and
a second initiator;
wherein the diluent reacts with the phosphoric acid monomer to crosslink at least the phosphoric acid monomer.
US Pat. No. 10,478,385

DENTAL ADHESIVE MATERIAL KIT

KURARAY NORITAKE DENTAL I...

1. A dental adhesive material kit comprising:a dental aqueous adhesive composition (A); and
a dental curable composition (B),
wherein
the dental aqueous adhesive composition (A) comprises a (meth)acrylic polymerizable monomer (a) comprising an acid group, a vanadium compound (b), water (c), a (meth)acrylic polymerizable monomer (d) comprising an amino group, and a polymerization inhibitor (i),
the content of the polymerization inhibitor (i) is 25 to 1000 parts by weight per 100 parts by weight of the vanadium compound (b), and
the dental curable composition (B) comprises a (meth)acrylic polymerizable monomer (e) comprising no acid group, a hydroperoxide (f), a photopolymerization initiator (g), and a filler (h), does not comprise a thiourea compound, and does not comprise borate compounds.
US Pat. No. 10,478,386

TWO-PART COSMETIC COMPOSITION FOR CHANGING COLOR OF KERATINIC FIBERS

1. A two-part cosmetic composition for changing color of keratinic fibers, comprising,(a) a gel-like part having a pH of from about 8 to about 12 and comprising,
optionally an oxidative dye precursor, and
a thickener selected from the group of xanthan gum, anionic amphiphilic polymer, and combination thereof, and
(b) an oxidizing part having a pH of from about 1 to about 5 comprising,
an oxidizing agent, and
a thickener comprising one or more anionic amphiphilic polymers;
wherein the two-part cosmetic composition has a viscosity of from about 1000 to about 200000 mPa·s measured using a Brookfield rotating spindle viscometer Model RVT at about 4 rpm and from about 20 to about 25° C.
US Pat. No. 10,479,924

PACKING FLUIDS AND METHODS

HALLIBURTON ENERGY SERVIC...

1. A packing fluid comprising:(a) an aqueous solvent;
(b) ammonium tungstate dissolved in the solvent; and
(c) one or more solid weighting agents,
the ammonium tungstate is in an amount such that the density of the packing fluid is from about 15 lbs/gal to about 22 lbs/gal.
US Pat. No. 10,478,132

GLUCOSE CONJUGATED GOLD NANOPARTICLE

BAR-ILAN UNIVERSITY, Ram...

1. A composition comprising:a gold nanoparticle;
PEG or derivatives thereof, wherein said PEG and derivatives thereof have a molecular weight of 400 to 1000 Dalton; and
a 2-Deoxy-D-glucose,
wherein said PEG or derivatives thereof are linked to said gold nanoparticle and to said 2-Deoxy-D-Glucose, wherein said PEG or derivatives thereof are linked to said gold nanoparticle via a chemical attachment selected from the group consisting of: covalent attachment, semi-covalent attachment and non-covalent attachment,
wherein said 2-Deoxy-D-Glucose is linked to said PEG and derivatives thereof at the 2-Carbon position of said 2-Deoxy-D-Glucose; and
wherein said composition has a diameter of 20 to 60 nanometers.
US Pat. No. 10,483,519

BATTERY PACK AND BATTERY PACK MANUFACTURING METHOD

Envision AESC Japan Ltd.,...

1. A battery pack comprising:a cell group obtained by stacking a plurality of unit cells in a thickness direction, the unit cells each including a cell body having a power generation element and a flat shape, and an electrode tab protruding out from the cell body, and the electrode tabs having distal end portions bent in a stacking direction of the unit cells; and
a flat plate shape bus bar connecting the distal end portions of the electrode tabs of the unit cells while facing the distal end portions, and electrically connecting the electrode tabs of at least two of the unit cells with each other, wherein:
each of the distal end portions of the electrode tabs of at least two of the unit cells and a surface of the bus bar that faces the unit cells are in contact and welded to each other,
the distal end portions of the electrode tabs that are electrically connected by the bus bar are bent in a same direction,
the cell group comprises spacers disposed between the electrode tabs of the unit cells that are stacked, the spacers including supporting portions that abut the electrode tabs from an opposite side of the bus bar to support the distal end portions of the electrode tabs, and
each of the spacers are attached to a respective one of the unit cells.
US Pat. No. 10,478,391

SKIN-CARE FORMULATION FOR TREATING ANTI-AGING AND WRINKLE REDUCTION

1. A formulation comprising:apitoxin;
a combination of Glycerin, Aqua, Dipeptide Diaminobutyroyl Benzylamide Diacetate equivalent biomimetic peptide;
?conotoxin CnCIII;
a combination of Glycerin, Aqua, Terminalia Ferdinandiana Fruit Extract;
at least one chelating agent;
wherein the at least one chelating agent is Tetrasodium Glutamate Diacetate that has a percentage range of 0.01-1.00% within the formulation;
deionized water that has a percentage range of 5-80% within the formulation;
at least one type of emollient that has a percentage range of 0.50-7.00% within the formulation;
wherein the at least one type of emollient is selected from a list consisting of Caprylic/Capric Triglyceride, Isononyl Isononanoate, Squalane and Pataua Oil;
at least one type of emulsifier that has a percentage range of 1.00-10.00% within the formulation;
wherein the at least one type of emulsifier is Hydrogenated Lecithin, C12-16 Alcohols, Palmitic Acid or Cetyl Alcohol, Glyceryl Stearate, PEG-75 Stearate, Ceteth-20 , Steareth-2 or both:
at least one a type of humectant, at least one a type of neutralizer, at least one a type of non-ionic surfactant/emulsifier and at least one a type of preservative; and
at least one a type of rheology modifier and at least one a type of sensorial modifier or mattifying agent.
US Pat. No. 10,478,392

PEPTIDE AND COSMETIC COMPOSITION COMPRISING SAME FOR PREVENTING SKIN AGING OR SKIN WRINKLE FORMATION

College of Medicine Pocho...

1. A peptide having an activity of facilitating bindings between keratinocytes and increasing expression of junction proteins, consisting of the sequence of SEQ ID NO: 2.
US Pat. No. 10,478,393

METHOD OF COSMETIC TREATMENT TO PROTECT THE SKIN FROM POLLUTION AND IMPROVE SKIN REGENERATION

ISP Investments LLC, Wim...

1. A cosmetic treatment method for protecting skin epidermal cells from DNA damages induced by ozone exposure and UVB irradiation, comprising topically applying to skin in need thereof an effective amount of a cosmetic composition wherein the composition comprises 0.5 to 2% of an active ingredient consisting of a combination of a hydrolysed rice extract and a grapeseed extract in a ratio adjusted at 9:1 (w/w) and a physiologically acceptable medium, wherein the process to prepare the active ingredient comprises the following steps:a. obtaining hydrolysed rice extract by enzymatic hydrolysis with vegetal enzymes, said hydrolysed rice extract is consisting of low molecular weight peptides of molecular weight less than 6 kDa,
b. purifying the hydrolysed rice extract using decreasing porosity filters;
c. obtaining the grapeseed extract from grapeseed cake in water at a pH between 4 and 7,
d. purifying the grapeseed extract using decreasing porosity filters; and
e. combining the extracts obtained at step b and d in a weight ratio of 9:1
f. adding 30% of glycerol in 70% of the product obtained at step e to prepare the active ingredient
g. using the active ingredient obtained at step f to prepare a cosmetic composition comprising the active ingredient at a weight ratio of 0.5 to 2% of the cosmetic composition.
US Pat. No. 10,479,931

POLYMER MOLDING COMPOSITION, WAVELENGTH CONVERTER, BACKLIGHT UNIT, AND LIQUID CRYSTAL DISPLAY DEVICE

FUJIFILM Corporation, To...

1. A composition comprising at least:quantum dots having an emission peak wavelength in a visible light region; and
quantum dots having an emission peak wavelength in an ultraviolet region or in a near-ultraviolet region.
US Pat. No. 10,478,394

COMPOSITIONS AND METHODS TO PROMOTE WOUND HEALING

Wayne State University, ...

1. A method of promoting healing of a chronic wound in a diabetic subject comprising administering to the chronic wound a therapeutically effective amount of a gel comprising a therapeutic agent consisting of a therapeutic protein consisting of the sequence provided in SEQ ID NO: 26 (anakinra), thereby promoting healing of the chronic wound.
US Pat. No. 10,478,395

PAMOATE SALTS AND METHODS OF USE

1. A pharmaceutical composition comprising a pamoate salt of rivastigmine and a pharmaceutically acceptable carrier.
US Pat. No. 10,478,396

THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

Rani Therapeutics, LLC, ...

1. A therapeutic preparation comprising parathyroid hormone (PTH), the preparation shaped as a solid tissue penetrating member and configured to penetrate and be inserted into an intestinal wall after oral ingestion, wherein upon insertion, the preparation releases PTH into the blood stream from the intestinal wall by degradation of the tissue penetrating member,wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member,
wherein a dose of PTH in the preparation is in a range from about 10 to 30 ?g,
wherein the preparation is adapted to be orally delivered in a swallowable capsule, and
wherein the preparation is adapted to be operably coupled to delivery means having a first configuration and a second configuration, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the intestinal wall in the second configuration.
US Pat. No. 10,479,934

STABILIZED SCINTILLATOR

1. A stabilized scintillator, comprising:a compound corresponding to formula (3), or activated derivatives thereof:
A2BB?XxX?y  (3)wherein A and B are monovalent cations, B? is a trivalent cation, X is a halogen, x and y are molar percentages, wherein x+y=6; X? is an aliovalent exchange anion that has a different valence than X;wherein a crystal of the stabilized scintillator is clear throughout;
wherein the stabilized scintillator has improved photoluminescence quantum yield over a base compound of structure (1)
A2sBB?X6  (1)
wherein A, B, B? and X are the same as above.
US Pat. No. 10,483,529

COMPOSITE POWDER FOR USE IN AN ANODE OF A LITHIUM ION BATTERY, METHOD OF PREPARING SUCH A COMPOSITE POWDER AND METHOD FOR ANALYSING SUCH A COMPOSITE POWDER

UMICORE, Brussels (BE) S...

1. A composite powder for use in an anode of a lithium ion battery, wherein particles of the composite powder comprise silicon-based domains in a matrix, and wherein the matrix comprises carbon or a precursor material that can be converted into carbon by thermal treatment, and wherein the individual silicon-based domains are either:free silicon-based domains that are not or not completely embedded in the matrix, or
fully embedded silicon-based domains that are completely surrounded by the matrix,wherein the percentage of free silicon-based domains is lower than or equal to 4 weight % of the total amount of Si in metallic or oxidized state in the composite powder, andwherein the silicon-based domains have a weight based size distribution with a d50 of 200 nm or less and a d90 of 1000 nm or less, and wherein the composite powder also comprises graphite, wherein the graphite is not embedded in the matrix.
US Pat. No. 10,479,681

FLUORINATING AGENT

DAIKIN INDUSTRIES, LTD., ...

1. A method for fluorinating a compound, the method comprising:bringing the compound into contact with a complex consisting of bromine trifluoride and at least one metal halide selected from the group consisting of halogenated metals and halogenated hydrogen metals.
US Pat. No. 10,477,885

TOMATO-DERIVED THICKENING AGENT

Conopco Inc., Englewood ...

1. A process for preparing a tomato-derived thickening agent comprising the steps of:a. providing a tomato pulp containing 3-15 wt. % tomato soluble solids (TSS) and 0.3-5 wt. % tomato insoluble solids (TIS);
b. isolating from said tomato pulp a tomato serum fraction having a reduced TIS content of less than 2.0 wt. % and a TSS content of at least 3 wt. %;
c. subjecting said tomato serum fraction to a filtration step to produce a retentate and a filtrate, said filtration step employing a membrane with a molecular weight cut-off (MWCO) in the range of 10-20,000 kDa;
d. collecting the retentate; and
e. drying the retentate to obtain the tomato-derived thickening agent.
US Pat. No. 10,483,531

NEGATIVE ELECTRODE ACTIVE MATERIAL FOR NONAQUEOUS ELECTROLYTE SECONDARY BATTERIES

1. A silicon-containing negative electrode active material for nonaqueous electrolyte secondary batteries, wherein the negative electrode active material particles comprise a surface layer comprising carbon and titanium or aluminum on an entirety or a portion of a surface of a core portion,wherein the core portion comprises: pure silicon; a silicon alloy selected from SiB4 or SiB6, Cu5Si, FeSi2, or Mg2Si; or a silicon compound selected from Si3N4 or SiC in an amount of 90% by mass or more, and
a content of titanium or aluminum in the surface layer is 0.002 to 0.07% by mass of the silicon-containing negative electrode active material particles.
US Pat. No. 10,477,886

FUNCTIONAL NUTRITIONAL BLEND FOR THERMO-METABOLIC PERFORMANCE

SAMI LABS LIMITED, Banga...

1. A composition for inhibiting adipogenesis in mammalian adipocytes consisting essentially of 70-73% w/w Gynostemma pentaphyllum extract, 12-15% w/w Coleus forskohlii extract, 10-12% w/w Zingiber officinale extract and 0.5-1% w/w Piperine.
US Pat. No. 10,478,401

METHODS FOR ENCAPSULATION AND MICROCAPSULES PRODUCED THEREBY

Proteon Pharmaceuticals S...

1. A method for encapsulating a material comprising the steps of:(a) providing an aqueous solution or suspension of the material that is to be encapsulated,
(b) warming the aqueous solution or suspension of material to be encapsulated to a temperature range of from 38° C. to 40° C.,
(c) adding a first biocompatible polymer comprising carboxylic groups for coordination to Zn2+ ions into the warmed aqueous solution or suspension of step (b) comprising the material to be encapsulated,
(d) de-aerating the solution or suspension obtained in step (c),
(e) emulsifying the solution or suspension obtained in (d) in a biocompatible oil comprising a surfactant to create microdroplets of the first biocompatible polymer and the material that is to be encapsulated,
(f) forming microcapsules by dropwise addition of an aqueous solution comprising Zn2+ ions and a second biocompatible polymer comprising a moiety for ionically binding the first biocompatible polymer to the emulsion obtained in (e), whereby the Zn2+ ions bind and cross-link the carboxylic groups of the first biocompatible polymer and the first biocompatible polymer ionically binds and cross-links the second biocompatible polymer to encapsulate the material to be encapsulated.
US Pat. No. 10,483,017

FLAME RETARDANT RESIN COMPOSITION, CABLE USING SAME AND OPTICAL FIBER CABLE

Fujikura Ltd., Tokyo (JP...

1. A flame retardant resin composition consisting essentially of:a base resin comprising 18 to 85% by mass of a high density polyethylene, 9 to 69% by mass of a low density polyethylene, and 3 to 25% by mass of a maleic anhydride modified ethylene-? olefin copolymer, and
25 parts by mass to 110 parts by mass of calcium carbonate particles, more than 1 part by mass to 10 parts by mass of a silicone-based compound, and 2 parts by mass to 20 parts by mass of a fatty acid-containing compound, each on the basis of 100 parts by mass of the base resin.
US Pat. No. 10,478,404

MATERIALS, METHODS AND DEVICES FOR ALTERING CELL REACTIVITY

Arizona Board of Regents ...

1. An ex vivo or in vivo method of treating human cells to modulate their reactivity to exogenous physical forces comprising administering to human cells subjected to exogenous physical forces, a composition comprising an effective amount of one or more agents selected from the group consisting of:(i) a lipid or lipid related compound, hormone, carbachol, atropine, inositol, DMSO, lidocaine, procaine, sex steroids, phenytoin, perylene, 9-(dicyanovinyl) julodinine, 1,6-diphenyl-1,3,5-hexatiene (DPH), TMA-DPH, DPH-PA, cis and trans-parinaric acid, wherein the hormone is selected from the group consisting of cortisol, estradiol, progesterone, medroxyprogesterone, insulin, glucagon, thyroid hormone, and aldosterone;
(ii) sulindac sulfide, phenolic antioxidants, caffeic acid phenethyl ester (CAPE) FAK signaling and modulating agents, resveratrol, Rho kinase inhibitors, Y-27632, inhibitors or modulators of talin, paxilin, and viculin and submembrane mechnotransductive proteins;
(iii) cytochlasins, concanavalin, vincristine, vinblastine, oryzalin, trifluralin, taxol, and taxetere;
(iv) colchicine, colcemid, 9 bromonscapine (EM011), docetaxel, noscapinoids, and tau; or
(v) hypo or hypertonic solutions, saline, lactated ringers, dextrose, sucrose, and mannitol, aqueporin receptors modulating agents, Hg Cl2, G-protein modulating agents, tolvaptan, convivaptan, and vaptans
wherein the exogenous physical force provides a shear stress greater than 50 dynes/cm2, wherein the method further comprising using a ventricular assist device (VAD) to pump blood in a patient's body, wherein the exogenous physical force is a force provided by the VAD.
US Pat. No. 10,479,686

SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS

Hope Medical Enterprises,...

1. A pharmaceutical composition comprising sodium thiosulfate pentahydrate and one or more pharmaceutically acceptable carriers or excipients, wherein the sodium thiosulfate pentahydrate contains no greater than 8 ppm of non-purgeable organic carbon, contains no greater than 0.05 ppm of mercury, contains no greater than 2 ppm of aluminum, contains no greater than 0.003% by weight of selenium, contains no less than 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a water content between 32% and 37% by weight, has a heavy metal content of no greater than 10 ppm, contains no greater than 200 ppm of chloride, contains no greater than 0.001% by weight of sulfide, contains no greater than 0.002% by weight of iron, contains no greater than 0.01% by weight of calcium, contains no greater than 0.005% by weight of potassium, contains no greater than 0.1% of sulfite, contains no greater than 0.5% of sulfate, contains no greater than 3 ppm of arsenic, contains no greater than 0.001% by weight of lead, has total aerobic count of microbial load of no greater than 100 CFU/g, has total yeast and mold count of no greater than 20 CFU/g, contains no greater than 0.02 EU/mg of bacterial endotoxins, contains no greater than 0.002% by weight of nitrogen compounds, contains no greater than 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein a 10% aqueous solution of the solid sodium thiosulfate pentahydrate at 25° C. is colorless and has a pH between 6.0 and 8.0, and wherein the solid sodium thiosulfate pentahydrate is odorless crystals,wherein the pharmaceutical composition is formulated for parenteral administration; and
wherein the pharmaceutically acceptable carrier or excipient is an aqueous vehicle; a water-miscible vehicle; a non-aqueous vehicle; an antimicrobial agent or preservative against the growth of microorganisms; a stabilizer; a solubility enhancer; an isotonic agent; a buffering agent; an antioxidant; a local anesthetic; a suspending or dispersing agent; a wetting or emulsifying agent; a complexing agent; a sequestering or chelating agent; a cryoprotectant; a lyoprotectant; a thickening agent; a pH adjusting agent; or an inert gas.
US Pat. No. 10,479,687

SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS

Hope Medical Enterprises,...

1. A pharmaceutical composition comprising sodium thiosulfate pentahydrate and one or more pharmaceutically acceptable carriers or excipients, wherein the sodium thiosulfate pentahydrate contains no greater than 8 ppm of non-purgeable organic carbon, contains no greater than 0.05 ppm of mercury, contains no greater than 2 ppm of aluminum, contains no greater than 0.003% by weight of selenium, contains no less than 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a water content between 32% and 37% by weight, has a heavy metal content of no greater than 10 ppm, contains no greater than 200 ppm of chloride, contains no greater than 0.001% by weight of sulfide, contains no greater than 0.002% by weight of iron, contains no greater than 0.01% by weight of calcium, contains no greater than 0.005% by weight of potassium, contains no greater than 0.1% of sulfite, contains no greater than 0.5% of sulfate, contains no greater than 3 ppm of arsenic, contains no greater than 0.001% by weight of lead, has total aerobic count of microbial load of no greater than 100 CFU/g, has total yeast and mold count of no greater than 20 CFU/g, contains no greater than 0.02 EU/mg of bacterial endotoxins, contains no greater than 0.002% by weight of nitrogen compounds, contains no greater than 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein a 10% aqueous solution of the solid sodium thiosulfate pentahydrate at 25° C. is colorless and has a pH between 6.0 and 8.0, and wherein the solid sodium thiosulfate pentahydrate is odorless crystals,wherein the pharmaceutical composition is an enteric-coated capsule or is formulated for rectal administration.
US Pat. No. 10,481,484

REFLECTIVE MASK BLANK, REFLECTIVE MASK, METHOD FOR MANUFACTURING REFLECTIVE MASK BLANK, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Tokyo ...

1. A reflective mask blank comprising:a substrate, and
a multilayer reflective film, a protective film, and a phase-shift film for shifting a phase of EUV light, which are formed in said order on the substrate,
wherein the protective film is made of a material containing ruthenium as a main component, and
wherein an anti-diffusion layer which contains ruthenium and oxygen is formed on a surface of the protective film, or as a part of the protective film on a side adjacent to the phase-shift film, so as to inhibit counter diffusion in relation to the phase-shift film.
US Pat. No. 10,481,485

MASK BLANK, TRANSFER MASK, METHOD OF MANUFACTURING TRANSFER MASK AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Tokyo ...

1. A mask blank comprising:a transparent substrate;
a thin film for pattern formation provided on a main surface of the transparent substrate;
an etching stopper film provided between the transparent substrate and the thin film for pattern formation,
wherein the thin film for pattern formation contains silicon;
wherein the etching stopper film is single layered film; and
wherein the etching stopper film contains silicon, aluminum, and oxygen.
US Pat. No. 10,478,408

COMBINATION TREATMENTS FOR OPIOID CRISIS

1. A method of reducing the chances of alcohol mediated opioid overdose or death during maintenance therapy for management of pain, comprising:selecting a subject for maintenance therapy for management of pain;
administering a single composition to the subject, comprising:
an effective amount of one or more opioid medications for the management of pain; and
an effective amount of one or more aldehyde dehydrogenase inhibitors sufficient to prevent alcohol consumption, the one or more aldehyde dehydrogenase inhibitors selected from disulfiram, calcium carbimide, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporins, antidiabetic sulfonyl ureas, metronidazole, ampal, benomyl, citral and active isomers thereof, chloral hydrate, chlorpropamide analogs, (benzoyloxy)[4-chlorophenyl)sulfonyl]carbamic acid 1,1-dimethylethyl ester (NPI-1), 4-chloro-N-ethyl-N-[(propylamino)carbonyl]benzenesulfonamid (API-1), 3-(((3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid (CVT-10216), N,N-diethylaminobenzaldehyde (DEAB), gossypol, molinate, nitroglycerin, pargyline, or pharmaceutically acceptable salts thereof, enabling provision of the powerful analgesic effects of the opioid in a manner which prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death during maintenance therapy for management of pain.
US Pat. No. 10,479,946

SYSTEM AND PROCESS FOR INCREASING HEAVY OILS CONVERSION CAPACITY

Eni S.p.A., Rome (IT)

1. A system for heavy oils hydroconversion comprising:a reactor,
a liquid-vapor separator, and
a stripping section of conversion products, external to said reactor, comprising a connection conduit between a reactor head of said reactor and said liquid-vapor separator and a supply conduit for supplying stripping gas at a point of said connection conduit,
wherein said connection conduit is upwardly inclined, at least from the point of supply of the stripping gas, with a gradient of between 2% and 20% with respect to a horizontal plane,
wherein obstacles are inserted inside said connection conduit between said reactor head and said liquid-vapor separator, which facilitates intimate mixing of the liquid and vapor phases and makes it possible for liquid/vapor equilibrium to be achieved.
US Pat. No. 10,481,486

MASK BLANK, PHASE SHIFT MASK, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Tokyo ...

1. A mask blank having a structure in which a phase shift film and a light shielding film are laminated in this order on a transparent substrate,wherein the phase shift film has a function to transmit exposure light of an ArF excimer laser at a transmittance of not less than 2% and not more than 30%, and a function to generate a phase difference of not less than 150 degrees and not more than 200 degrees between the exposure light transmitted through the phase shift film and the exposure light transmitted through air for the same distance as a thickness of the phase shift film,
wherein the phase shift film is formed from a material containing silicon and not substantially containing chromium, and includes a structure in which a lower layer and an upper layer are laminated from the transparent substrate side,
wherein the lower layer has a refractive index n lower than the transparent substrate at a wavelength of the exposure light,
wherein the upper layer has a refractive index n higher than the transparent substrate at a wavelength of the exposure light,
wherein the lower layer has an extinction coefficient k higher than the upper layer at a wavelength of the exposure light,
wherein the light shielding film includes a layer in contact with the phase shift film, and
wherein the layer in contact with the phase shift film is formed from a material containing chromium, has a refractive index n lower than the upper layer at a wavelength of the exposure light, and has an extinction coefficient k higher than the upper layer at a wavelength of the exposure light.
US Pat. No. 10,479,179

METHOD FOR OPERATING A RECHARGEABLE BATTERY CELL AND BATTERY CONTROL DEVICE

Robert Bosch GmbH, Stutt...

1. A method for operating a rechargeable battery cell (2), the method comprising:measuring (101) a first voltage (U1) of the battery cell (2),
comparing (102) the first voltage (U1) with a first limit voltage (Umax1),
charging (104) the battery cell (2) if the first voltage (U1) is less than the first limit voltage (Umax1),
measuring (106) a second voltage (U2) of the battery cell (2),
comparing (107) the second voltage (U2) with a second limit voltage (Umax2),
discharging (109) the battery cell (2) if the second voltage (U2) is greater than the second limit voltage (Umax2),
wherein the first limit voltage (Umax1) is greater than the second limit voltage (Umax2).
US Pat. No. 10,479,694

PROCESS OF CLEAN PRODUCTION OF ELECTRONIC GRADE HIGH-PURITY COPPER OXIDE

1. A process of clean production of an electronic grade high-purity copper oxide, comprising the following steps in sequence:(1) continuously preparing a carbon-ammonia system solution, wherein the molar ratio of CO2:NH3:H2O is 1:1.3-2:17-20;
(2) adding the carbon-ammonia system solution into a reaction vessel preloaded with metallic copper, and constantly inputting air, oxygen or ozone under a negative pressure of between ?0.01 and ?0.02 Mpa to keep the temperature of the reaction system equal to or less than 60° C.; the negative pressure is closed when the concentration of copper in the carbon-ammonia system solution reaches 80-140 g/L;
(3) filtering the copper, carbon-ammonia system solution to a reaction kettle for deamination, adding sodium polyacrylate to obtain a reaction solution after stirring evenly; the reaction solution is heated to a temperature of 60-80° C. under a pressure of between ?0.03 and ?0.08 MPa for deamination and ammonia water is collected during deamination, wherein the sodium polyacrylate is added in an amount of 0.2-0.6 g/L based on a volume of the copper, carbon-ammonia system solution filtrate;
(4) separating solid from liquid by a centrifuge obtaining a copper carbonate including copper and collecting a copper-containing clear solution;
(5) calcining the copper carbonate at a temperature of 250-600° C. for 1-5 hours to give an electronic grade high-purity copper oxide, and carbon dioxide and water vapor are produced during the calcination; the ammonia water collected in the above step (3), the copper-containing clear solution collected in the step (4) and carbon dioxide and water vapor collected in the step (5) are directly used as raw materials to prepare the carbon-ammonia system solution, wherein the copper-containing clear solution is used as water.
US Pat. No. 10,479,950

QUATERNARY AMMONIUM AMIDE AND/OR ESTER SALTS

The Lubrizol Corporation,...

1. A composition comprising a quaternary ammonium salt detergent containing an amide group, where the quaternized detergent comprises the reaction product of:(a) a non-quaternized detergent containing an amide group, where the detergent has a tertiary amine functionality; and
(b) a quaternizing agent;
and wherein the reaction of (a) and (b) is essentially free of any additional acid component other than an acid group present in the structure of the detergent; and wherein (b) the quaternizing agent comprises ethylene oxide, propylene oxide, butylene oxide, styrene oxide, or combinations thereof.
US Pat. No. 10,483,544

LITHIUM SECONDARY BATTERIES

SK Innovation Co., Ltd., ...

1. A lithium secondary battery comprising: an anode containing agglomerate artificial graphite having pores with an average diameter of 80 to 150 nm; and an electrolyte solution having a viscosity of 5.0 cP or less at 25° C.,wherein the agglomerate artificial graphite satisfies the following Equation 1:
0.1??HA/HA?0.4
wherein HA is an average particle diameter (?m) of the agglomerate artificial graphite; and ?HA is an average particle diameter variation (?m) of the agglomerate artificial graphite when applying a pressure of 4 mN/cm2,
wherein the electrolyte solution contains a first solvent including ethylmethyl carbonate, diethyl carbonate or a mixed solution thereof and a second solvent including at least one selected from dimethyl carbonate (DMC), dipropyl carbonate (DPC), methylpropyl carbonate (MPC), ethylpropyl carbonate (EPC), ethylene carbonate (EC), propylene carbonate (PC), and butylene carbonate (BC).
US Pat. No. 10,478,414

NEUROREGENERATION SUPPLEMENT

1. A composition for enhancing neuroregenation of peripheral nerves of a mammal consisting:between about 40 and 48 percent of L-glycine;
between about 10 and 15 percent L-glutamine; and
between about 30 and 37 percent D, L-phenylalanine of the composition.
US Pat. No. 10,479,954

INTRINSIC LOW FRICTION POLYOXYMETHYLENE

Celanese Sales Germany Gm...

1. A polyoxymethylene polymer composition, the polyoxymethylene polymer composition comprising;a polyoxymethylene copolymer having a melt flow index of less than about 50 g/10 min, and
first tribological modifier comprising an ultra-high molecular weight silicone having a kinematic viscosity at 40° C. of greater than 100,000 mm2 s?1, the ultra-high molecular weight silicone being present in the polymer composition in an amount from about 0.1 to about 10% by weight;
a second tribological modifier comprising polytetrafluoroethylene particles, ultra-high molecular weight polyethylene, or a silicone oil having an average molecular weight of at least 5,000 g/mol and less than 75,000 g/mol and having a kinematic viscosity at 40° C. of greater than 100 mm2 s?1 and less than 15,000 mm2 s?1, or mixtures thereof; and
reinforcing fibers present in the composition in an amount of at least 10% by weight and up to 50% by weight.
US Pat. No. 10,478,417

FORMULATION FOR EFFECTIVE TOCOTRIENOL DELIVERY

KL-KEPONG OLEOMAS SDN BHD...

1. A method of delivering a tocotrienol to a subject in need of supplementing an intake of a daily allowance of a fat-soluble nutrient, the method comprising administering to the subject a dietary supplement comprising a self-emulsifying formulation comprising a fat-soluble compound selected from tocotrienols and derivatives thereof, wherein the amount of the fat-soluble compound is about 10% to about 50%, by weight of the formulation; two emulsifiers each selected from the group consisting of nonionic surfactants, wherein the emulsifiers are sorbitan monolaurate and polyoxyethylene sorbitan 20 monooleate (Polysorbate 80), wherein the amount of emulsifiers is about 15% to about 45%, by weight of the formulation, wherein the weight ratio of said sorbitan monolaurate to Polysorbate 80 is about 1:1 to about 1:20; andan oil carrier selected from the group consisting of glycerides, wherein the amount of oil carrier is about 6% to about 56%, by weight of the formulation.
US Pat. No. 10,479,955

LUBRICATING GREASE COMPOSITION

Nok Klueber Co., Ltd., T...

1. A lubricating grease composition for a resin member used to be supplied as a lubricant on a surface of at least a sliding portion of a resin member including the sliding portion with another member, wherein the lubricating grease composition for a resin member containsa base oil which consists of a mixed oil of: a poly-?-olefin having a kinetic viscosity at 40° C. of 18 to 30 mm2/s, and an ethylene-?-olefin copolymer having a number average molecular weight of 40,000 to 200,000,
a lithium-based complex soap as a thickener, and
a polytetrafluoroethylene resin as a solid lubricant having a mixing ratio of 4 to 12 mass % to the entire lubricating grease composition,
wherein the base oil, which is the mixed oil of the poly-?-olefin and the ethylene-?-olefin copolymer, has a kinetic viscosity at 40° C. of 80 to 200 mm2/s, and
a worked penetration of the lubricating grease composition ranges from 295 to 340.
US Pat. No. 10,481,495

TOPCOAT COMPOSITIONS CONTAINING FLUORINATED THERMAL ACID GENERATORS

Rohm and Haas Electronic ...

1. A topcoat composition, comprising:a matrix polymer;
a surface active polymer;
an ionic thermal acid generator comprising an anion and a cation, wherein the anion, the cation, or the anion and the cation are fluorinated, wherein the cation is of the general formula (I):
(BH)+  (I)
which is the monoprotonated form of a nitrogen-containing base B; and
a solvent.
US Pat. No. 10,478,418

INHIBITED EXPRESSION OF PD-L1 AND ENHANCED EXPRESSION OF PD-1

IN Ingredients, Inc., Sp...

1. A method of treating a glioma in a human in need thereof comprising administering to said human in need thereof a composition comprising at least 5.0 weight % isolated cinnamtannin D-1, at least 5.0 weight % isolated cinnamtannin B-1, or a combination thereof to effectively treat the glioma in said human in need thereof.
US Pat. No. 10,479,700

SYSTEM AND METHOD OF DESALINATION

1. A method of desalination of sea water, comprising:provision of a sealed reservoir disposed at the edge of the sea, comprising a filling device disposed on the roof, along with one or more openings disposed below sea level and being in communication with the sea;
filling of the reservoir with sea water by the filling device, with the openings being hermetically sealed, followed by closing of the filling device to render the reservoir sealed;
opening of the openings, placing the water which is inside the reservoir in communication with the water of the sea, wherewith the water level in the reservoir will decrease and will stabilize at a height h above the level of the sea, wherewith water vapor is produced in the reservoir above said height h, and wherewith the ceiling of the reservoir will have a height above the level of the sea greater than the height h to allow treatment of the water vapor produced in the reservoir;
condensation of the water vapor produced, to obtain desalinated water; and
removal of water from the water surface located at a height h in the reservoir toward the sea, in order to maintain the temperature of the water at the surface of the reservoir at the temperature of the water of the sea.
US Pat. No. 10,478,163

MEDICAL INSTRUMENT ENGAGEMENT PROCESS

Intuitive Surgical Operat...

1. A method for operating a medical instrument and a drive system, the medical instrument comprising at least one component, comprising:bringing a first feature on a rotatable element of the medical instrument into contact with a second feature on a drive element of the drive system without restricting a rotation angle of the first feature relative to the second feature, the second feature being shaped to engage the first feature, and the medical instrument including a mechanism coupled to the rotatable element and coupled to actuate the at least one component of the medical instrument in response to rotation of the rotatable element;
applying an engagement force to create friction between the first and second features, wherein bringing the first feature into contact with the second feature and applying the engagement force engages the first and the second features without inducing rotation that actuates the medical instrument; and
operating the drive system to rotate the drive element and the rotatable element, wherein the friction transfers torque that the drive element applies to the rotatable element to rotate the rotatable element and thereby to actuate the component.
US Pat. No. 10,479,957

LUBRICANT FOR METAL COLD FORMING PROCESSES AND METHODS OF USE OF THE SAME

FREIBORNE INDUSTRIES, INC...

1. A lubricant for use in cold forming of a metal consisting essentially of:one or more lubricating compounds selected from the group consisting of a soap that is a metal salt of a C6 to C22 fatty acid, a soap that is a metal salt of a C6 to C22 fatty acid containing one or more hydroxyl function groups, boric acid, a metal salt of boric acid, boron nitride, zinc oxide, calcium oxide, molybdenum disulfide, an emulsion of polyethylene, an emulsion of high density polyethylene, an emulsion of polypropylene, an emulsion of maleated polypropylene, an emulsion of a urethane, an emulsion of an oxidized polyethylene, an emulsion of an oxidized high density polyethylene, an emulsion of an oxidized polypropylene, an emulsion of an oxidized maleated polypropylene, an emulsion of an oxidized urethane, and mixtures thereof;
one or more starches;
wherein a weight:weight ratio of a total amount of said one or more lubricating compounds to a total amount of said one or more starches in said lubricant is in a range of from 1:1 to 8:1;
optionally, including at least one additional component selected from the group consisting of a surfactant, a corrosion inhibitor, a processing aid, a bactericidal agent, a bacteriostatic agent, a fungistatic agent, a fungicidal agent, a defoaming agent, a viscosity modifier, a pH buffering agent, or mixtures thereof, wherein a total amount of said at least one additional component does not exceed 5% by weight based on a total weight of said lubricant; and
wherein said lubricant is a solid at 75° F.
US Pat. No. 10,478,420

ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES

ObsEva S.A., Plan-les-Ou...

1. A method of treating infertility in a human patient, the method comprising administering to the patient a dispersible tablet comprising a substantially pure form of (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime and one or more pharmaceutically acceptable excipients.
US Pat. No. 10,477,908

ACRYLIC FIBER FOR ARTIFICIAL HAIR, METHOD FOR PRODUCING SAME, AND HEAD DECORATION PRODUCT COMPRISING SAME

KANEKA CORPORATION, Osak...

1. An acrylic fiber for artificial hair, comprising an acrylic polymer and an organic solvent that can dissolve the acrylic polymer,wherein the acrylic polymer comprises, with respect to a total weight of the acrylic polymer, 29.5 to 79.5% by weight of acrylonitrile, 20 to 70% by weight of vinyl chloride and/or vinylidene chloride, and 0.5 to 5% by weight of a sulfonic acid-containing vinyl monomer,
wherein a content of the organic solvent in the acrylic fiber is 0.1 to 3% by weight, and
wherein the acrylic fiber has a single fiber fineness of 30 to 100 dtex.
US Pat. No. 10,478,422

ORAL LIQUID COMPOSITIONS INCLUDING VALSARTAN

ECI PHARMACEUTICALS, LLC,...

1. An oral liquid solution comprising:3.6 mg/mL to 4.4 mg/mL valsartan or a pharmaceutically acceptable salt or solvate thereof; and
9.3 mg/mL to 10.7 mg/mL citrate salt;
provided that a pH of the oral liquid solution is from 5.8 to 6.1 and the oral liquid solution exhibits a stability for 18 months;
provided that the valsartan or the pharmaceutically acceptable salt or solvate thereof is fully solubilized in the oral liquid solution; and
provided that administration of a 320 mg dose of the oral liquid solution to a patient provides an in vivo plasma profile having a valsartan AUCinf in a range from 35,162 ng*hr/mL to 72,130 ng*hr/m L.
US Pat. No. 10,483,554

CARBON SUPPORT FOR FUEL CELL CATALYST AND PREPARATION METHOD THEREOF

KOREA INSTITUTE OF SCIENC...

1. A method for preparing a nitrogen-doped carbon support for a fuel cell catalyst, the method comprising:(A) mixing a conductive carbon support with a nitrogen-containing organic material;
(B) primarily annealing the mixture at 90 to 150° C. for 2 to 10 hours in a normal air atmosphere so as to react nitrogen atoms of the nitrogen-containing material with the support; and
(C) secondarily annealing the primarily annealed mixture at 600 to 750° C. under a nitrogen atmosphere
so as to completely dope the nitrogen atoms into the support.
US Pat. No. 10,479,962

SOLID COMPOSITION FOR TEXTILE TREATMENT

1. A solid composition for use in treatment of textiles comprising:a sodium percarbonate present as a powder or granules in a total amount of about 32% to about 55% by weight based on the total weight of the composition,
tetraacetylethylenediamine present in a total amount of from about 10% to about 20% by weight based on the total weight of the composition,
a sodium hydrogen carbonate present as a powder or granules in a total amount of from about 7.5 to about 30% by weight based on the total weight of the composition, and
a surfactant present in a total amount of from about 1 to about 3% by weight based on a total weight of the composition,
wherein the total amount of organic compound in the solid composition amounts to from about 10% to about 50% by weight, and
wherein the solid composition is free of sodium silicate.
US Pat. No. 10,479,963

MICROCAPSULES CONTAINING MICROORGANISMS

Devan Chemicals NV, Rons...

1. A composition comprising a microorganism within unruptured microcapsules, the composition comprising:friable microcapsules having a diameter from 1 to 300 ?m in a concentration of from 0.1% to 50% by weight of the composition dispersed within an aqueous treatment solution, the microcapsules being present in the composition in an amount for the microcapsules to be applied at a level of 0.1 to 20 gram/m2 when applied to a textile surface, the microcapsules adapted for delivery of a liquid onto the textile by rupture during conventional use of said textile, the microcapsules comprising a shell encapsulating the liquid to form a liquid core, the liquid containing a microorganism that consumes organic matter deposited on the textile surface;
wherein said microorganism is in a vegetative state, and is brought back into a reproductive state by contact with oxygen and moisture upon the rupture of the microcapsule.
US Pat. No. 10,478,939

POLISHING METHOD

FUJIMI INCORPORATED, (JP...

1. A polishing method for polishing an object to be polished containing tungsten and at least one of silicon oxide film and silicon nitride by using a polishing composition, the polishing method comprisingequalization of the surface zeta potential of said tungsten and at least one of said silicon oxide film and said silicon nitride,wherein the equalization is carried out by including a potential equalizing agent having an adsorbing group for adsorption onto said tungsten and at least one of said silicon oxide film and said silicon nitride and a functional group for providing zeta potential in the polishing composition,wherein the potential equalizing agent is dicyandiamide diethylenetriamine formalin condensate.
US Pat. No. 10,478,427

THERAPEUTIC AGENT FOR FIBROSIS AND INHIBITOR OF NUCLEAR TRANSLOCATION OF PHOSPHORYLATED SMAD

NATIONAL UNIVERSITY CORPO...

1. A method for treating fibrosis caused by nuclear translocation of phosphorylated Smad, wherein the fibrosis is idiopathic pulmonary fibrosis, comprising administrating a therapeutic agent for the fibrosis whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, which inhibitor has the activity of inhibiting nuclear translocation of phosphorylated Smad and is contained in a therapeutically effective amount, said inhibitor(s) being a sole inhibitor or sole inhibitors administrated during and for treatment of the fibrosis.
US Pat. No. 10,478,432

COMPOSITIONS OF MATTER FOR TREATMENT OF OPHTHALMIC CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM THE EYE

Unity Biotechnology, Inc....

1. A unit dose of a pharmaceutical composition formulated for treating of an ophthalmic disease or disorder in a subject in need thereof;wherein the ophthalmic disease is not a cancer;
wherein the composition comprises an amount of a small-molecule means for selectively inhibiting Bcl-2 or Bcl-xL;
wherein the unit dose is formulated with an excipient in a volume suitable for intravitreal administration; and
wherein the formulation of the composition and the amount of the means for selectively inhibiting Bcl-2 or Bcl-xL in the unit dose configure the unit dose to be effective in selectively killing p16 positive senescent cells in the eye that are causing adverse symptoms of the ophthalmic disease or disorder in the subject when administered to the subject intravitreally as a single dose.
US Pat. No. 10,478,946

OPEN MESH ABRASIVE MATERIAL

KEYON S.R.L., Verona (IT...

1. A process for the preparation of an open mesh abrasive material, comprising the following steps:a) impregnating only a second side of an open mesh support with a binder;
b) applying abrasive granules on said second side; and
c) drying the material obtained resulting in the open mesh abrasive material;
wherein a first side of the open mesh support is not-impregnated and is a teaseled side and wherein the second side of the open mesh support is the impregnated side and is a non-teaseled side.
US Pat. No. 10,483,049

LITHIUM ION CAPACITOR

TAIYO YUDEN CO., LTD., T...

1. A lithium ion capacitor having an electrolytic solution that contains:an electrolyte which is a mixture of LiFSI and LiBF4 which are the only lithium salts used as the electrolyte, where the mol ratio of LiFSI to LiBF4 is in a range of 90/10 to 30/70;
a solvent that contains at least one cyclic or chained carbonate compound; and
a film-forming agent which suppresses reductive decomposition of the solvent by reductively decomposing itself at a potential higher than that of the solvent, thereby forming a film on a negative electrode;
wherein a concentration of electrolyte in the electrolytic solution is in a range of 1.2 to 1.8 mol/L.
US Pat. No. 10,481,513

TONER FOR ELECTROSTATIC CHARGE DEVELOPMENT

KONICA MINOLTA, INC., To...

1. A toner for electrostatic charge development, comprising a toner particle, the toner particle comprising: a toner base particle containing a binder resin and a release agent; and an external additive containing titanium dioxide, whereinthe number fraction of the toner particle containing the titanium dioxide is 0.1% or more and 2.0% or less.
US Pat. No. 10,479,975

METHODS OF MAKING T CELL COMPOSITIONS

bluebird bio, Inc., Camb...

1. A method for manufacturing T cells comprising:a) activating a population of T cells and stimulating the population of T cells to proliferate;
b) transducing the T cells with a viral vector comprising a polynucleotide encoding an engineered T cell receptor (TCR) or a chimeric antigen receptor (CAR); and
c) culturing the transduced T cells to proliferate;
wherein steps a)-c) are performed in the presence of a phosphatidylinositol-3 kinase (PI3K) inhibitor, and
wherein T cell differentiation is decreased in the T cells manufactured according to steps a)-c) performed in the presence of the PI3K inhibitor compared to T cell differentiation in T cells manufactured according to steps a)-c) performed in the absence of the PI3K inhibitor.
US Pat. No. 10,478,438

TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH OCINAPLON

1. A method of treating exposure to sarin, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ocinaplon.
US Pat. No. 10,479,977

OSTEOCHONDRORETICULAR STEM CELLS FOR BONE AND CARTILAGE REGENERATION

The Trustees of Columbia ...

1. A method of treating a disease, degeneration, or injury of bone, or cartilage, or both, in a subject comprising administering a therapeutically effective amount of a composition comprising an acceptable carrier and isolated osteochondroreticular (OCR) stem cells that express Grem1 to a site in need thereof in the subject, wherein the isolated OCR stem cells are at least about 70% pure.
US Pat. No. 10,478,441

METHOD FOR THE TREATMENT OF DRAVET SYNDROME

THE KATHOLIEKE UNIVERSITE...

1. A method of stimulating 5-HT receptors in the brain of a patient diagnosed with Dravet syndrome, comprising:administering to the patient 0.2 mg/kg/day of fenfluramine or a pharmaceutically acceptable salt thereof; and
administering to the patient an effective dose of stiripentol or a pharmaceutically acceptable salt thereof;
whereby 5-HT receptors are stimulated and wherein the 5-HT receptor is in a family of receptors selected from the group consisting of 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7.
US Pat. No. 10,479,981

DNASE VARIANTS

1. A DNase variant, comprising:a polypeptide having at least 90% sequence identity to SEQ ID NO: 1;
wherein the polypeptide includes an amino acid substitution at position 39 of SEQ ID NO: 1 that is S39V or S39R;
wherein the polypeptide has DNase activity; and
wherein the polypeptide has improved stability as compared to the polypeptide of SEQ ID NO: 1.
US Pat. No. 10,479,726

FIBERSIZING WITH SMALL AMOUNTS OF NANOMATERIALS

Evonik Degussa GmbH, Ess...

1. A nanoparticle-coated fibre material, comprising a fibre material and a coating on at least a portion of the fibre material, wherein:the coating comprises from 0.01 wt % to less than 0.4 wt % of nanoparticles based on a dry weight of the nanoparticle-coated fibre material;
the coating is capable of undergoing further reactions; and
the nanoparticles comprise surface-modified spherical silica nanoparticles.
US Pat. No. 10,479,983

VARIANT ENZYMES

DANISCO US INC, Palo Alt...

1. A variant glycoside hydrolase family 61 (GH61) polypeptide, wherein said variant has cellulase enhancing activity, has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:3 and the amino acid substitution I114L, and has at least one improved property relative to a parent GH61 polypeptide, wherein said improved property is selected from the group consisting of (a) expression based on protein level and RNA level or activity of the variant GH61 polypeptide, (b) thermostability and/or melting temperature (Tm), (c) performance in a Whole Hydrolysate Dilute Acid Pretreated Corn Stover (whPCS) hydrolysis assay.
US Pat. No. 10,479,984

POLYPEPTIDES HAVING CELLOBIOHYDROLASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

1. A polypeptide comprising a carbohydrate binding module operably linked to a catalytic domain, wherein the carbohydrate binding module is heterologous to the polypeptide, and wherein the carbohydrate binding module is selected from the group consisting of:(a) a carbohydrate binding module having at least 95% sequence identity to amino acids 517 to 545 of SEQ ID NO: 2;
(b) a carbohydrate binding module comprising amino acids 517 to 545 of SEQ ID NO: 2; and
(c) a carbohydrate binding module encoded by a polynucleotide having at least 98% sequence identity to nucleotides 1549 to 1635 of SEQ ID NO: 1.
US Pat. No. 10,478,448

METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION

Ionis Pharmaceuticals, In...

1. A method of treating, slowing the progression of, or ameliorating a symptom of hyperlipidemia in a subject, comprising:administering to said subject a compound comprising a modified oligonucleotide, wherein:
the modified oligonucleotide consists of 14 to 25 linked nucleosides and comprises a nucleobase sequence comprising a portion of at least 14 contiguous nucleobases complementary to an equal length portion of nucleobases 3900 to 3923 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to SEQ ID NO: 1, including any salt thereof, whereby the administration treats, slows the progression of, or ameliorates a symptom of hyperlipidemia in the subject.
US Pat. No. 10,479,986

NUCLEIC ACID CONSTRUCTS AND METHODS FOR LABELING AND DETECTING NUCLEOSOMAL DNA MODIFICATIONS

The Broad Institute, Inc....

1. A method for labeling nucleic acids from a cell or population of cells comprising:providing one or more individual discrete volumes, each individual discrete volume comprising a cell or population of cells;
lysing the cell or population of cells in each individual discrete volume and fragmenting nucleosomal DNA from the lysed cell or population of cells;
labeling the fragmented nucleosomal DNA in each individual discrete volume with a barcoded adapter on at least one free end of the fragmented nucleosomal DNA, wherein:
the barcoded adapter comprises an amplification promoter adjacent to a first or second read sequencing primer binding site which is adjacent to a barcode sequence,
the labeled nucleosomal DNA comprises, in a 3? to 5? orientation, a first read sequencing primer binding site, the nucleosomal DNA sequence, the barcode sequence, and a second read sequencing primer binding site,
the barcode sequence is unique to each individual discrete volume thereby identifying a sample from which the labeled nucleosomal DNA originated;
isolating and sequencing the labeled nucleosomal DNA from each sample; and
grouping the sequenced nucleosomal DNA by common barcode thereby identifying the individual discrete volumes from which the nucleosomal DNA originated.
US Pat. No. 10,478,449

2?-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS

Ionis Pharmaceuticals, In...

1. A composition comprising a first oligomer and a second oligomer, wherein:at least a portion of said first oligomer is capable of hybridizing with at least a portion of said second oligomer,
at least a portion of said first oligomer is complementary to and capable of hybridizing with a selected target nucleic acid,
each of said first and second oligomers are chimeric oligomers,
wherein the second oligomer has an internal segment comprising at least five consecutive nucleosides having a 2?-OCH3 substituent group, and
wherein the chimeric oligomers are not gapmers.
US Pat. No. 10,483,580

SOLID STATE FUEL CELL AND METHOD FOR MAKING THE SAME

National Taipei Universit...

1. A solid state fuel cell comprising an anode, a cathode, and a ceramic electrolyte including a silicate oxyapatite represented byREy?xMxSi6O27±?
where RE is a rare earth metal, M is an alkali metal, x is greater than 0 and less than 1, y ranges from 9.3 to 10, and ? ranges from 0 to 2.
US Pat. No. 10,478,450

METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON

Luitpold Pharmaceuticals,...

1. A method of treating a disease, disorder, or condition characterized by iron deficiency or dysfunctional iron metabolism resulting in reduced bioavailability of dietary iron, comprising administering to a subject in need thereof an iron carbohydrate complex in a single dosage unit of at least 0.7 grams of elemental iron, wherein:the iron carbohydrate complex is substantially non-immunogenic, and has substantially no cross reactivity with anti-dextran antibodies; and
the iron carbohydrate complex is an iron polyisomaltose complex.
US Pat. No. 10,479,733

POWDER COMPRISING POLYMER-COATED CORE PARTICLES COMPRISING METALS, METAL OXIDES, METAL NITRIDES OR SEMIMETAL NITRIDES

Evonik Degussa GmbH, Ess...

1. A powder, comprising composite particles:wherein the composite particles, comprise:
a core particle; and
a coating of a precipitated polymer on the core;
wherein
a thickness of the precipitated polymer coating of the composite particle is from 1.5 to 35 ?m,
the core particle is at least one material selected from the group consisting of a metal, a metal nitride, a semimetal nitride and a metal oxide selected from the group consisting of Al2O3, ZrO2, ZnO, Bi2O3, CeO2, ITO (indium oxide doped with tin(IV) oxide), having a d50 median diameter of from 1 to 100 ?m,
the precipitated polymer of the coating comprises at least one polymer selected from the group consisting of nylon-11, nylon-12, PA1010, PA1012, PA1212 and PA1013,
the melting point of the precipitated polymer in a first heating procedure is greater than in a second heating procedure, as measured by differential scanning calorimetry (DSC),
a ratio of a d50 median diameter of the composite particles to the d50 median diameter of the core particles is 1.15 to 30, and
the melting point of the precipitated coating polymer is obtainable when the polymer is exposed to an electromagnetic energy.
US Pat. No. 10,479,989

COMPOSITIONS FOR MAKING RANDOM CODON-MUTANT LIBRARIES AND USES THEREOF

Fred Hutchinson Cancer Re...

1. A method for making a plurality of variant nucleic acid molecules, comprising(a) amplifying a reference nucleic acid molecule template with a plurality of forward mutagenic oligonucleotides to produce a first plurality of forward mutagenic fragments and separately amplifying the reference nucleic acid molecule template with a plurality of reverse mutagenic oligonucleotides to produce a first plurality of reverse mutagenic fragments, wherein the reference nucleic acid molecule template comprises a plurality of codons that encode a reference polypeptide and wherein each of the plurality of forward and reverse mutagenic oligonucleotides comprise a codon randomized at one to three nucleotides and the oligonucleotides comprise from nine to 100 nucleotides, and wherein the randomized codons correspond to all codons of the reference nucleic acid molecule template except the initiation codon;
(b) purifying the first plurality of forward and reverse mutagenic fragments and mixing the purified first plurality of forward and reverse mutagenic fragments to produce a first mixed mutagenic nucleic acid molecule fragment template composition; and
(c) joining the mixed nucleic acid molecule fragments of the first mixed mutagenic nucleic acid molecule fragment template composition by amplifying in a single reaction with the plurality of forward and reverse mutagenic oligonucleotides from step (a) to produce a first plurality of joined mutagenic nucleic acid molecules;
thereby introducing codon variants at random locations at a controlled mutation rate across the length of the reference nucleic acid molecule template.
US Pat. No. 10,479,992

RNA DUPLEXES WITH SINGLE STRANDED PHOSPHOROTHIOATE NUCLEOTIDE REGIONS FOR ADDITIONAL FUNCTIONALITY

Phio Pharmaceuticals Corp...

1. An isolated double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the passenger strand is 8-16 continuous nucleotides in length, wherein the isolated double stranded nucleic acid molecule comprises a double stranded region that is 8-16 nucleotides in length, wherein the guide strand is 19-25 nucleotides in length, and wherein the double stranded region is connected through a cleavable chemical linker to a single stranded region of at least six phosphorothioate modified nucleotides.
US Pat. No. 10,478,456

PHARMACEUTICAL PREPARATION

APOSCIENCE AG, Vienna (A...

1. A pharmaceutical preparation, comprising a dosage form of a cell-free culture supernatant of peripheral blood mononuclear cells (PBMCs), the cell-free culture supernatant comprising at least 2000 pg/mL of matrix metallopeptidase 9 (MMP-9) and no detectable amount of TNF-?, the PBMCs comprising non-activated, non-proliferating T cells, B cells, NK cells, and monocytes cultivated under a stress inducing condition comprising a dose of at least 10 Gy radiation in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
US Pat. No. 10,479,994

ROTATIONALLY SEQUESTERED TRANSLATORS

Emerald Therapeutics, Inc...

1. A composition comprising:(a) a first nucleic acid complex comprising (i) a first nucleic strand comprising, sequentially, a first, second and third fragments and defined as S-Q-P, wherein each letter denotes a fragment and a string of letters connected by “-” denotes a strand, and (ii) a second strand comprising, sequentially, a first, second, third and fourth fragments and defined as A- B- P- Q, wherein the first complex comprises a duplex region (Q-P::P- Q) formed between the second and third fragments of the first strand and the third and fourth fragments of the second strand; and
(b) a second nucleic acid complex comprising (i) a first nucleic acid strand comprising, sequentially, a first, second and third fragments and defined as P-B- ?, (ii) a second nucleic acid strand comprising, sequentially, a first, second and third fragments and defined as A-X-C, and (iii) a third strand comprising, sequentially, a first, second and third fragments and defined as D- X- B, wherein the second complex comprises a first duplex region (?::A) formed between the third fragment of the first strand and the first fragment of the second strand, a second duplex region (B::B) formed between the first fragment of the first strand and the third fragment of the third strand, and a third duplex region (X::X) formed between the second fragment of the second strand and the second fragment of the third strand,
wherein the first (S) fragment of the first strand of the first complex, the first (A) and second (B) of the second strand of the first complex, the first fragment (P) of the third strand of the second complex, the third fragment (C) of the second strand of the second complex, and the first fragment (D) of the third strand of the second complex are single-stranded; and
wherein the first, second and third fragments (A, B, P) of the second strand of the first complex have sequence complementarity to the third, second and first fragments (?, B, P) of the first strand of the second complex to allow binding therebetween, respectively.
US Pat. No. 10,478,457

CHIMERIC PROTEIN

UCL BUSINESS LTD, London...

1. A chimeric protein having the formula:Ht1-Ht2-Casp, wherein
Casp is a caspase domain;
Ht1 is a first heterodimerization domain; and
Ht2 is a second heterodimerization domain;
wherein one heterodimerization domain comprises an FK506-binding protein (FKBP) and the other heterodimerization domain comprises an FRB domain of mTOR;
and wherein, in the presence of rapamycin or a rapamycin analog, an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains.
US Pat. No. 10,479,995

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

WAVE LIFE SCIENCES LTD., ...

1. An oligonucleotide having the structure of:mG*SmGmCmAmC*SA*SA*SG*SG*SG*SC*SA*SC*RA*SG*SmAmCmUmU*SmC (SEQ ID NO: 360), or a pharmaceutically acceptable salt thereof, wherein:
*S represents a Sp phosphorothioate;
*R represents a Rp phosphorothioate; and
m represents a 2?-OMe modification to a nucleoside.
US Pat. No. 10,478,458

IN VITRO PRE-CONDITIONED BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AND USES THEREOF

THE JOHNS HOPKINS UNIVERS...

1. A composition comprising:an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs),
wherein at least 80% of the in vitro pre-conditioned BMSC population express PGP9.5 and NSE,
wherein at least 70% of the in vitro pre-conditioned BMSC population express Tuj1 and HuC/D,
wherein at least 75% of the in vitro pre-conditioned BMSC population express neuronal nitric oxide synthase (nNOS), and
wherein the BMSCs promote de novo regeneration of neurons not originated from the BMSCs when the BMSCs are administered to a subject.
US Pat. No. 10,478,459

COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION

UNIVERSITE CATHOLIQUE DE ...

1. A combination comprising:a liquid cell suspension comprising adult liver-derived progenitor or stem cells and at least one factor Xa inhibitor which is a direct or indirect factor Xa inhibitor and is not an antithrombin activator, and
at least one thrombin inhibitor.
US Pat. No. 10,478,461

CELLULAR EXTRACTS

REGENICS AS, Oslo (NO)

1. A method of improving wound healing in a human subject, comprising:applying a composition comprising a trout egg cellular extract having a protein content of from about 210-270 mg/ml and an RNA content from about 3.51 to 4.68 mg/ml to a wound of said subject under conditions such wound healing is improved, wherein said improvement is selected from the group consisting of faster drying, faster reepithelialization, reduced inflammation, faster contraction, earlier remodeling, reduction in scar tissue and improved visual appearance of the wound and combinations thereof.
US Pat. No. 10,479,745

CATALYTIC ISOMERIZATION OF Z-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE TO E-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE

THE CHEMOURS COMPANY FC, ...

1. A process for isomerizing Z-1,1,1,4,4,4-hexafluoro-2-butene to E-1,1,1,4,4,4-hexafluoro-2-butene comprising:(a) providing a starting material comprising Z-1,1,1,4,4,4-hexafluoro-2-butene;
(b) contacting the starting material with a suitable catalyst in a reaction zone to produce E-HFO-1336mzz; and optionally,
(c) recovering the E-HFO-1336mzz,
wherein, when the contacting step is performed in the gas phase, the catalyst comprises chromium and less than 40% by weight alumina;
wherein when the contacting step is performed in the liquid phase, the catalyst comprises a metal halide wherein the metal halide is aluminum halide, antimony halide, tin halide, tantalum halide, titanium halide, niobium halide, molybdenum halide, iron halide, fluorinated chrome halide, or combinations thereof.
US Pat. No. 10,480,001

METHOD FOR THE GENERATION OF A MONOCLONAL PLANT CELL LINE

1. A method for the generation of a monoclonal plant cell line from a heterogeneous population of plant cells, comprising the following steps:(a) providing a heterogeneous population of plant cells;
(b) preparing a heterogeneous population of protoplasts from the heterogeneous population of plant cells, wherein at least one of the protoplasts from the prepared heterogeneous population of protoplasts is transformed with at least one expression vector encoding at least one fluorescent protein and a resistance against at least one selection agent;
(c) initiating cell wall regeneration in said heterogeneous population of protoplasts for fluorescence activated cell sorting (FACS);
(d) providing a cell deposition device containing feeder cells in liquid medium containing wells;
(e) sorting by FACS the prepared at least one protoplast from the heterogeneous population of protoplasts in which the cell wall regeneration has been initiated, wherein said at least one protoplast is highly fluorescent;
(f) separating the sorted at least one protoplast into at least one different liquid medium-containing well containing the feeder cells for monoclonal plant cell generation such that said at least one well for monoclonal plant cell line generation contains a single prepared protoplast permitted to directly contact the feeder cells;
(g) regenerating the single separated protoplast from said at least one well into a microcolony by co-cultivating the separated protoplast in the same well as the feeder cells; and
(h) removing the microcolony from the feeder cells and cultivating the microcolony in the presence of said at least one selection agent against which said at least one protoplast is transformed with said at least one expression vector encoding a resistance until a monoclonal plant cell line from said at least one protoplast is established.
US Pat. No. 10,478,464

COMPOSITIONS AND METHODS OF USE

Kirit Shah, Portland, OR...

1. A method of treating cancer in a subject comprising administering to the subject a composition comprising an effective amount of 8-hydroxyhexadecanoic acid, or a salt thereof, thereby treating said cancer;wherein said cancer is a lung cancer.
US Pat. No. 10,479,746

METHOD FOR PRODUCING AND PURIFYING 2,3,3,3-TETRAFLUORO-1-PROPENE

ARKEMA FRANCE, Colombes ...

1. A process for purifying 2,3,3,3-tetrafluoro-1-propene (1234yf) using a first composition comprising 2,3,3,3-tetrafluoro-1-propene and at least one compound selected from the group consisting of 1,1-difluoroethane (152a), chloropentafluoroethane (115) and trans-1,3,3,3-tetrafluoro-1-propene (1234ze-E), said process comprising:a) placing said first composition in contact with at least one organic extracting agent to form a second composition;
b) distilling said second composition by extractive distillation to form:
i) a third composition comprising said organic extracting agent and said at least one compound selected from the group consisting of 1,1-difluoroethane (152a), chloropentafluoroethane (115) and trans-1,3,3,3-tetrafluoro-1-propene (1234ze-E); and
ii) a stream comprising 2,3,3,3-tetrafluoro-1-propene; and
c) recovering and separating said third composition to form a stream comprising said organic extracting agent and a stream comprising said at least one compound selected from the group consisting of 1,1-difluoroethane (152a), chloropentafluoroethane (115) and trans-1,3,3,3-tetrafluoro-1-propene (1234ze-E).
US Pat. No. 10,480,002

ALGAL BASED EDIBLE VACCINES

TRANSALGAE ISRAEL LTD., ...

1. An edible vaccine comprising a transgenic eukaryotic microalga, the transgenic microalga comprising an expression cassette comprising at least one polynucleotide encoding an exogenous antigen further comprising a polynucleotide encoding a vacuolar targeting peptide having the amino acid sequence set forth in any one of SEQ ID NO:1 and SEQ ID NO:9, wherein the encoded exogenous antigen is localized within the vacuole of the microalga cell, and wherein said encoded exogenous antigen induces an immune response in a target subject consuming said vaccine against a disease caused by a pathogen.
US Pat. No. 10,483,595

TUNGSTEN-BASED MATERIAL SUPER BATTERY AND SUPERCAPACITOR

SUZHOU HANS ENERGY STORAG...

1. An electrochemical energy storage and conversion device that comprises:an aqueous electrolyte solution; and
at least one of:
a tungsten carbon super battery having one electrode made of a tungsten material and another electrode made of carbon;
a tungsten and tungsten super battery having one electrode and another electrode that are each made of a tungsten trioxide material;
a tungsten lead oxide super battery having one electrode made of the tungsten trioxide material and another electrode made of lead oxide; and
a hybrid super battery that is constructed by the tungsten carbon super battery and the tungsten lead oxide super battery connected in parallel or in series,
wherein the tungsten material and the tungsten trioxide material are each at least one selected from the group consisting of:
(a) a hydrous tungsten trioxide (WO3.nH2O) having a crystal structure selected from the group consisting of a cubic crystal structure, a hexagonal structure, a bi-continuous structure, and combinations thereof, and wherein n is a value in the range of 0 (b) the hydrous tungsten trioxide of section (a), which is doped with an element A (AxWO3.nH2O), wherein the element A is at least one element selected from the group consisting of an alkali metal that is either sodium or potassium, an alkaline earth metal that is either calcium or strontium, a transition metal that is either titanium or zirconium, and a rare metal that is either lanthanum or cerium, and x is a value in the range of 0 (c) a mixture or composite material that consists of a tungsten-free material and at least one of the hydrous tungsten trioxide of section (a) and the hydrous tungsten trioxide of section that is doped with the element A of section (b), wherein the tungsten-free material is selected from the group consisting of:
a carbon material that is selected from the group consisting of carbon black, onion structured carbon particles, activated carbon, mesoporous carbon, carbon nanotubes, carbon nanofiber, graphite, graphene, graphene oxide, combinations thereof,
a polymer material that is selected from the group consisting of polyaniline, polypyrrole, polythiophene, poly (3,4-ethylenedioxythiophene), polystyrene, sulfonated polystyrene, and combinations thereof,
a metal or salt thereof that is selected from the group consisting of vanadium, chromium, zirconium, niobium, molybdenum, lead, bismuth, and combinations thereof, and
a ceramic material that is selected from the group consisting of zirconium oxide, silicon oxide, strontium oxide, aluminum oxide, and combinations thereof.
US Pat. No. 10,479,747

FIRE RETARDANT COMPOUNDS

The Boeing Company, Chic...

1. A fire extinguishing unit comprising a container and delivery system, the container containing a fire extinguishing compound having the formula:(F3C)C(R2)=CR3R4 whereinR2 is iodo and R3 and R4 are both fluoro or R3 is hydrogen and R4 is fluoro;
R2 is bromo, R3 is bromo and R4 is iodo; or
R2 is fluoro, R3 is chloro, and R4 is iodo.
US Pat. No. 10,478,468

METHOD FOR ENHANCING EFFECT OF IMMUNOTHERAPY FOR CANCER

PHYTOHEALTH CORPORATION, ...

1. A method for increasing a subject's pool of M1 macrophages, wherein the subject is suffering from one or more conditions associated with undesirable M2 macrophage activation, the method comprisingadministering to the subject an effective amount of a polysaccharide extract of Astragalus membranaceus, said polysaccharide extract comprising an arabinose:galactose ratio ranging from about 1.5:1 to about 3:1; from about 5% to about 15% arabinose; less than about 1.5% rhamnose; from about 3% to about 7% galactose; less than about 4% galacturonic acid; and, from about 70% to about 90% glucose.
US Pat. No. 10,480,006

PESTICIDAL GENES AND METHODS OF USE

AGBIOME, INC., Research ...

1. A recombinant polypeptide, comprisinga polypeptide comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 36, wherein said polypeptide has pesticidal activity and further comprises a heterologous amino acid sequence chemically linked to said polypeptide.
US Pat. No. 10,479,751

PROCESS FOR PREPARING ACRYLIC ACID

Evonik Degussa GmbH, Ess...

1. An apparatus consisting essentially ofa feed containing a reaction mixture arranged below the middle of the apparatus,
a quenching agent inlet arranged above the feed,
an outlet arranged below the feed and
a draw arranged above the quenching agent inlet,the apparatus having, between the quenching agent inlet and the feed containing the reaction mixture, a region provided with one or more packing elements, wherein 2 or 3 sieve trays or ripple trays which ensure the formation of a liquid layer having a height of at least 1 cm is present between the quenching agent inlet and a packing element present between the quenching agent inlet and feed containing the reaction mixture, the liquid layer being arranged in the apparatus such that gaseous substances which pass through the feed containing the reaction mixture into the apparatus have to pass through the liquid layer in order to get into the top of the apparatus.
US Pat. No. 10,480,007

INSECTICIDAL PROTEINS FROM PLANTS

PIONEER HI-BRED INTERNATI...

1. A recombinant PtIP-50 polypeptide comprising an amino acid sequence having at least 95% sequence identity, across the entire length of the amino acid sequence, compared to the amino acid sequence of SEQ ID NO: 71, wherein the PtIP-50 polypeptide has insecticidal activity against Soy Bean Looper, Corn Earworm, European Corn Borer or Velvet Bean Caterpillar in combination with a PtIP-65 polypeptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 22, wherein the PtIP-50 polypeptide is operably linked to a heterologous signal or leader sequence.
US Pat. No. 10,480,008

INSECTICIDAL POLYPEPTIDES HAVING BROAD SPECTRUM ACTIVITY AND USES THEREOF

POINEER HI-BRED INTERNATI...

1. An isolated nucleic acid molecule operably linked to a heterologous regulatory element, wherein said isolated nucleic acid is selected from the group consisting of:(a) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3;
(b) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4;
(c) a nucleic acid molecule comprising a nucleotide sequence encoding a protein, having insecticidal activity against soybean looper, comprising an amino acid sequence that differs by 1 to 3 amino acid resides compared to the amino acid sequence of SEQ ID NO: 4; and
(d) a nucleic acid molecule comprising a nucleotide sequence encoding a protein, having insecticidal activity against soybean looper, comprising an amino acid sequence that differs by 1 to 3 amino acid resides compared to the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,478,471

IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide consists of the amino acid sequence of VFIFKGNQF (SEQ ID NO: 18), wherein the peptide is in a complex with an MHC molecule.
US Pat. No. 10,478,473

COMPOSITIONS AND METHODS OF USING ANTI-MULLERIAN HORMONE FOR TREATMENT OF INFERTILITY

THE CENTER FOR HUMAN REPR...

1. A method for treating infertility in a subject comprising administering to the subject an effective amount of a composition comprising anti-Mullerian hormone (AMH), wherein the AMH comprises the amino acid sequence set forth in SEQ ID NO:1; and wherein the AMH is administered at a dose in the range of about 22,000 ng/day to about 44,000 ng/day for a period of time from about 30 days to about 90 days.
US Pat. No. 10,478,474

THYMOSIN ALPHA 1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS

SciClone Pharmaceuticals ...

1. A method of treating cystic fibrosis in a patient comprising administering a pharmaceutical composition comprising Thymosin alpha 1 to the patient, wherein the patient has a cystic fibrosis transmembrane conductance regulator (CFTR) mutation ?F508.
US Pat. No. 10,480,012

CYP-P22 BIOCATALYTIC NANOPARTICLES WITH CYTOCHROME P450 ACTIVITY FOR PRODRUG ACTIVATION

UNIVERSIDAD NACIONAL AUTO...

1. An immunologically inert and functionalized CYP-P22 biocatalytic nanoparticle that activates prodrugs in a target cell, comprisinga) a polypeptide sequence of SEQ ID NO:4 which is a fusion of a scaffold protein SP and a CYPBM3 protein,
b) a fragment of a P22 scaffold protein,
c) a coat protein of P22 bacteriophage,
d) a bifunctional dendritic polyethylene glycol, and
e) a cyclic polypeptide of SEQ ID NO: 5.
US Pat. No. 10,478,475

USE OF VON WILLEBRAND FACTOR

LABORATOIRE FRANCAIS DU F...

1. A method of treating or preventing haemorrhage and/or bleeding in patients with mechanical circulatory support, comprising administering to the patient a pharmaceutical composition comprising von Willebrand factor in an amount effective for treating or preventing haemorrhage and/or bleeding in patients with mechanical circulatory support, wherein the composition contains a residual amount of factor VIII less than or equal to 10 IU/100 IU VWF:RCo, and wherein the composition is administered to the patient at a dose of 45 IU/kg to 55 IU/kg of body weight.
US Pat. No. 10,479,757

N,N-DIMETHYLAMINOETHYL ACRYLATE COMPOSITION STABILIZED IN RESPECT OF DISCOLORING EFFECTS

Arkema France, Colombes ...

1. A process for the continuous production of a composition of N,N-dimethylaminoethyl acrylate that is stabilized with respect to coloration, comprising from 25 to 200 ppm of 2,6-di-tert-butyl-4-methylphenol, said process comprising the steps of transesterifying a light acrylate selected from the group consisting of methyl acrylate and ethyl acrylate, with dimethylaminoethanol in the presence of a catalyst, followed by a treatment for purifying a reaction mixture comprising a final distillation of purified N,N-dimethylaminoethyl acrylate, wherein 25 to 200 ppm of 2,6-di-tert-butyl-4-methylphenol are introduced at an outlet of the distilled gaseous stream of purified N,N-dimethylaminoethyl acrylate, before condensation of final product.
US Pat. No. 10,480,013

INFLUENZA VIRUS VECTOR FOR VIROTHERAPY

BLUE SKY VACCINES GMBH, ...

1. A recombinant influenza B virus vector comprising an NS gene encoding a truncated NS1 protein consisting of 106 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector:(i) replicates in IFN-sensitive tumor cells and in IFN-resistant tumor cells, and is attenuated in normal cells, and
(ii) expresses a heterologous immunostimulatory polypeptide, wherein the heterologous polypeptide is a tumor associated antigen.
US Pat. No. 10,478,476

USE OF FULL-LENGTH AMELOGENIN FOR PROMOTING NERVE GROWTH OR REGENERATION

Hadasit Medical Research ...

1. A method of promoting nerve growth or regeneration in a subject in need thereof, the method comprising directly administering to an injured nerve of the subject a therapeutically effective amount of full-length amelogenin, thereby promoting nerve growth or regeneration in the subject, wherein said injured nerve is a peripheral or a spinal cord nerve.
US Pat. No. 10,480,014

METHOD FOR PRODUCING NATURAL RUBBER BY USING RECOMBINANT MICROORGANISM

AJOU University Industry-...

1. A method for producing natural rubber by using a recombinant microorganism, comprising the steps of:(a) constructing an expression vector capable of expressing a gene encoding for cis-prenyltransferase, which is a guayule-derived natural rubber synthase having the amino acid sequence of SEQ ID NO: 2 or a Hevea brasiliensis-derived natural rubber synthase having the amino acid sequence of SEQ ID NO: 6, and an expression vector capable of expressing a gene encoding for an E. coli-derived UDP pyrophosphate synthase having the amino acid sequence of SEQ ID NO: 4;
(b) transforming the expression vectors into a host microorganism;
(c) culturing the transformed host microorganism; and
(d) isolating natural rubber from a culture of the transformed host microorganism.
US Pat. No. 10,478,477

METHOD FOR PROPHYLAXIS OR TREATMENT OF ERBB1 POSITIVE CANCERS USING A VARIANT PEPTIDASE D WITH REDUCED ACTIVITY

Health Research, Inc., B...

1. A method for prophylaxis or therapy of ErbB1-positive cancer in an individual comprising administering to the individual an effective amount of a composition comprising peptidase D (PEPD), the PEPD comprising the sequence of SEQ ID NO:1 with a mutation of G278, such that growth of the ErbB1-positive cancer is inhibited.
US Pat. No. 10,479,760

SYNTHETIC METHODS FOR THE PREPARATION OF PROPYLENE AMMOXIDATION CATALYSTS

Clariant Corporation, Lo...

1. A process for producing a catalyst material, the catalyst material comprisingan inert carrier having a specific surface of 1 to 500 m2/g in an amount in the range of about 25 wt % to about 75 wt %, and
a metal oxide catalyst in an amount in the range of about 25 wt % to about 75 wt %, the metal oxide catalyst having the formula MoxBiyFezNiaCeb1Mab2Mnb3Kd1Csd2Ov, wherein
x is in the range of 12 to 14;
y is in the range of 0.05 to 0.4;
z is in the range of 1 to 2.5;
a is in the range of 5 to 7;
b1 is in the range of 0.2 to 0.6;
b2 is in the range of 1 to 3;
b3 is in the range of 0.1 to 1.0;
d1 is in the range of 0.01 to 0.15;
d2 is in the range of 0.01 to 0.8; and
v is the number of oxygen atoms required to satisfy the valence requirements of the other component elements Mo, Bi, Fe, Ni, Ce, Mg, Mn, K, and Cs,the process comprising:providing a metal oxide precursor fluid comprising a solvent in admixture with a plurality of metal oxide precursors, the plurality of metal oxide precursors comprising at least
a molybdenum oxide precursor,
a bismuth oxide precursor, and
an iron oxide precursor,
wherein less than about 20 wt % of each of the molybdenum oxide precursor, the bismuth oxide precursor, and the iron oxide precursor is not dissolved in the solvent;
impregnating the inert carrier with the metal oxide precursor fluid to provide impregnated carrier;
drying the impregnated carrier to provide a dried, impregnated carrier; and
heating the dried, impregnated carrier to provide the catalyst material.
US Pat. No. 10,480,016

GENETICALLY ENGINEERED MICROORGANISMS FOR BIOLOGICAL OXIDATION OF HYDROCARBONS

Calysta, Inc., Menlo Par...

1. A non-naturally occurring bacterium, comprising:a host methanotrophic bacterium having an exogenous nucleic acid encoding an enzyme with methane monooxygenase (MMO) activity,
wherein the MMO comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOS: 99-102, 174, 197, and 649-653;
wherein at least one alcohol dehydrogenase enzyme is inactivated in the non-naturally occurring bacterium as compared to the host methanotrophic bacterium; and
wherein the non-naturally occurring bacterium is capable of converting methane into methanol.
US Pat. No. 10,480,019

PROCESS FOR PRODUCING HIGH-PURITY RUBUSOSIDE

PureCircle Sdn Bhd, Kual...

1. A process for preparing Rubusoside from steviol glycosides of Stevia rebaudiana comprising the steps of:A) providing a solution comprising Stevioside;
B) adding 2000 fungal ?-glucanase (FBG) units of an enzyme composition having fungal ?-glucanase activity to the solution comprising Stevioside to obtain a reaction mixture; and
C) incubating the reaction mixture at 28-50° C. for 12-48 hours to facilitate transformation of Stevioside to Rubusoside to obtain a reaction mixture containing Rubusoside.
US Pat. No. 10,478,482

VACCINES FOR PREVENTION AND TREATMENT OF TUBERCULOSIS

ALARUM DEVELOPMENT LTD, ...

1. A method of eliciting an immune response against Mycobacterium tuberculosis in a mammalian subject comprising the step of administering to said subject an immunological composition consisting essentially of a first isolated polypeptide of the amino acid sequence of SEQ ID NO: 1, a second isolated polypeptide of the amino acid sequence of SEQ ID NO: 2, and a third isolated polypeptide of the amino acid sequence of SEQ ID NO: 3 and at least one of a pharmaceutically acceptable carrier and an adjuvant.
US Pat. No. 10,480,020

RAPID TEST FOR MICROBIAL RESISTANCES BY MASS SPECTROMETRY

1. Sample support for a mass spectrometric determination of the resistance of a microbial sample to be applied to the sample support, wherein the sample support plate is flat and has on its surface a multiplicity of test sites and at least one test site is coated with a dosed quantity of one or more antibiotics and with one or more reference substances.
US Pat. No. 10,478,483

COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS

GLAXOSMITHKLINE BIOLOGICA...

1. An immunogenic composition which comprises an immunologically effective amount of an adjuvant, an immunologically effective amount of a first isolated factor H binding protein (fHbp) antigen and an immunologically effective amount of a second isolated fHbp antigen, wherein: the first isolated fHbp antigen comprises a first amino acid sequence which has at least 75% sequence identity to both of SEQ ID NO: 1 and SEQ ID NO: 23, but the first amino acid sequence has a higher sequence identity to SEQ ID NO: 1 than to SEQ ID NO: 23, when aligned using the same algorithm and parameters; and the second isolated fHbp antigen comprises a second amino acid sequence which has at least 75% sequence identity to both of SEQ ID NO: 1 and SEQ ID NO: 23, but the second amino acid sequence has a higher sequence identity to SEQ ID NO: 23 than to SEQ ID NO: 1, when aligned using the same algorithm and parameters.
US Pat. No. 10,478,485

METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS

THE BOARD OF REGENTS OF T...

1. An Acinetobacter baumanni mutant having a full or partial deletion in the thioredoxin-A (TrxA) gene that results in a non-functional TrxA gene.
US Pat. No. 10,478,486

IMMUNIZATION AGENTS AND METHODS OF USE

HSF PHARMACEUTICALS SA, ...

1. A method of immunization of a mammalian subject comprising (a) administering to an inoculation site region in the body of the mammalian subject a composition comprising an effective amount of a replication-competent controlled herpesvirus which is a recombinant virus in which one or more replication-essential genes have been placed under the control of a gene switch that is inserted in the genome of the recombinant virus and that can be activated deliberately, and (b) exposing the inoculation site region in the body of the mammalian subject to a localized activation treatment that activates the recombinant virus to undergo a round of replication in the inoculation site region wherein the replication-competent controlled herpesvirus comprises a gene encoding an influenza virus antigen.
US Pat. No. 10,478,487

FOOT-AND-MOUTH DISEASE VACCINE

Zoetis Services LLC, Par...

1. A method of herd management, comprising administering to each member in said herd the immunogenic composition wherein said composition comprises:a) antigen component comprising between about 8 ?g and 10 ?g of FMD (Foot-and-Mouth Disease) virus composition per dose;
b) an emulsion containing an oil;
c) 75-200 ?g of a CpG-containing immunostimulatory oligonucleotide per dose;
d) 75-200 mg of a polycationic carrier per dose, and
wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are not slaughtered.
US Pat. No. 10,478,491

METHODS FOR ENHANCING THE EFFICACY OF A TUMOR-DIRECTED IMMUNE RESPONSE

AUGUSTA UNIVERSITY RESEAR...

1. A method for enhancing an immune response against a tumor antigen in a subject, the method comprising administering to the subject an OX40 agonist antibody or an antigen-binding fragment thereof, 1-methyltryptophan (1-MT), and an immunogenic composition comprising an HPV antigen, thereby enhancing the subject's immune response against the tumor antigen relative to administration of the immunogenic composition and the OX40 agonist antibody or an antigen-binding fragment thereof.
US Pat. No. 10,479,774

METHOD FOR SEPARATING FLAVONOID SUBSTANCES IN CAMELLIA NITIDISSIMA CHI BASED ON A MAGNETIC NANOPARTICLES-PAMAM NANO COMPOSITES

Shenzhen Violin Technolog...

1. A method for separating flavonoid substances in Camellia nitidissima Chi based on magnetic nanoparticle-PAMAM nano composites, comprising:preparing PAMAM dendrimer:
performing Michael addition reaction between ethylenediamine and methyacrylate to obtain generation 0.5 polyamidoamine dendrimer, namely PAMAM G0.5; wherein the Michael addition reaction is performed under 25° C.;
reacting the obtained PAMAM G0.5 with excessive ethylenediamine under 25° C. to obtain generation 1.0 polyamidoamine dendrimer, namely PAMAM G1.0;
repeating the above two steps to obtain PAMAM with different generation;
preparing magnetic nanoparticle-PAMAM nano composites
dispersing magnetic nanoparticles into methanol through magnetic separation to obtain methanol solution with 0.0128 mol/L concentration;
diluting 25 mL methanol solution containing magnetic nanoparticles therein to 150 mL by methanol and performing ultrasonication for 30 min;
adding 10 mL 3-aminopropyltriethoxysilane, stirring and performing ultrasonication for 7 hours; performing magnetic separation on the obtained solution after washing it by methanol for 5 times; dispersing the washed solution in methanol to obtain 5 wt % magnetic nanoparticle methanol solution;
adding 200 mL methanol solution with methyacrylate into 50 mL 5 wt % magnetic nanoparticle methanol solution to obtain a mixed solution, wherein a volume concentration of the methyacrylate is 20%;
performing ultrasonication to the mixed solution for 7 hrs in water bath at room temperature;
collecting magnetic nanoparticles by magnet and washing it for 5 times by methanol and performing magnetic separation;
adding 40 mL methanol solution with ethylenediamine, the volume concentration of the ethylenediamine is 20%, performing ultrasonication for 3 hrs at room temperature;
washing the magnetic nanoparticles for 5 times with methanol and performing magnetic separation; repeatedly adding the methanol solution with methyacrylate and methanol solution with ethylenediamine; obtaining higher generations of magnetic nanoparticles modified by dendrimer for each cycle;
washing the solution after cycle with 25 mL methanol for 3 times and washing with 25 mL water for 5 times; and obtaining the magnetic nanoparticles modified by PAMAM dendrimer by magnetic separation; and
extracting and performing magnetic separation on the flavonoid substances in Camellia nitidissima Chi:
adding the obtained magnetic nanoparticle-PAMAM nano composites in a Camellia nitidissima Chi extract;
extracting for 0.5-3 hrs under ultrasound or microwave condition;
separating the nanoparticle-PAMAM nano composites adsorbed and extracted with flavonoid substances through magnetic separation after the extraction, the flavonoid substances adsorbed by magnetic nanoparticles are extracted and separated by using an organic solvent from separated nanoparticle-PAMAM nano composites.
US Pat. No. 10,478,493

METHOD OF TREATING PROTOZOAL GASTROINTESTINAL DISORDERS IN IMMUNOCOMPROMISED PATIENTS

Stolle Milk Biologics, In...

1. A method of treating cryptosporidiosis or isosporiasis in an immunocompromised animal which comprises:administering to said immunocompromised animal a product comprised of a vitamin and mineral blend (Vitamins B1, B2, B6, B12, Folate, D3, C, E, and minerals Magnesium and Zinc), probiotics, including but not limited to Lactobacillus and Bifidobacterium species, mixed with a hyperimmune milk product containing a biologically active component which reduces a number of oocysts in a stool, reduces a number of Cryptosporidia or Isospora parasites in an intestine or alleviates symptoms of cryptosporidiosis or isosporiasis in a subject infected with Cryptosporidia or Isospora from a hyperimmunized milk-producing mammal selected from the group consisting of cows, sheep, and goats, in amounts sufficient to treat said cryptosporidiosis or isosporiasis, wherein said hyperimmune milk product is selected from the group consisting of hyperimmune whole milk, hyperimmune whole milk fractions, and derivatives of hyperimmune whole milk, selected from the group consisting of hyperimmune skim milk, whey, protein concentrates, and isolates, which contain said biologically active component and is prepared by a process comprising:
(i) hyperimmunizing said milk-producing mammal with a mixture of heat-killed, non-protozoan bacterial antigens consisting of Staphylococcus simulans; Salmonella enteritidis; Streptococcus pneumoniae; Streptococcus sanguis; Streptococcus salivarius; Staphylococcus epidermidis; Streptococcus pyogenes, A. Type 1; Streptococcus pyogenes, A. Type 3; Streptococcus pyogenes, A. Type 5; Streptococcus pyogenes, A. Type 8; Streptococcus pyogenes, A. Type 12; Streptococcus pyogenes, A. Type 14; Streptococcus pyogenes, A. Type 18; Streptococcus pyogenes, A. Type 22; Escherichia coli; Escherichia coli ATCC 884; Escherichia coli ATCC 26; Salmonella enteritidis; Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella typhimurium, Haemophilus influenza; Streptococcus mitis; Proteus vulgaris; Shigella dysenteriae; Streptococcus pneumonia; Propionibacter acnes; Streptococcus sanguis; Streptococcus salivarius; Streptococcus mutans; and Streptococcus agalactiae;
(ii) collecting milk from said milk-producing mammal after said milk-producing mammal reaches a hyperimmune state;
(iii) filtering said milk through a molecular sieve which excludes proteins of molecular weight greater than 100,000 daltons;
(iv) blending said filtered milk retentate with the said vitamin and mineral blend and probiotics; and
(v) testing the blend of step (iv) for its ability to reduce the number of oocysts in the stool, reduce the number of Cryptosporidia or Isospora parasites in the intestine or alleviate symptoms of cryptosporidiosis or isosporiasis in a subject infected with Cryptosporidia or Isospora by administering to said subject the blend of step (iv) and measuring the reduction of said oocysts, parasites, or symptoms.
US Pat. No. 10,480,031

METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS)

The United States of Amer...

1. A method for producing human retinal pigment epithelial (RPE) cells, comprising:(a) culturing human induced pluripotent stem cells (hiPSCs) in a human embryonic stem cell culture medium comprising human basic fibroblast growth factor (bFGF) and not containing ingredients obtained from non-human animals to produce small embryoid bodies of 200-500 cells;
(b) culturing the small embryoid bodies from step (a) in a first medium comprising retinal induction medium (RIM) and rock inhibitor (RI), wherein the RIM comprises Wnt inhibitor CK1-7, a Nodal pathway inhibitor, Noggin, and 1 to 3% v/v knockout serum replacement, wherein the Nodal pathway inhibitor is SB-431542 or SB-505124, to form embryoid bodies that have increased efficiency of RPE differentiation;
(c) culturing the embryoid bodies that have increased efficiency of RPE differentiation from step (b) on a matrigel coated tissue culture substrate-in a second medium comprising a retinal differentiation medium that does not comprise basic fibroblast growth factor (bFGF) and comprises Dickkopf-related protein 1 (DKK1), CK1-7, a bFGF inhibitor, and Noggin, wherein the bFGF inhibitor is PD0325901, PD98059, PD161570, or PD166285, to form differentiating RPE cells that express PAX6 and MITF;
(d) culturing the differentiating RPE cells from step (C) in a third medium comprising retinal media comprising Activin A and Wnt3a to produce cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency; and
(e) culturing the cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency from step (d) in a fourth medium comprising a RPE cell medium comprising a non-canonical Wnt 5a inducer, DKK1, SU5402, and cyclopamine to produce human RPE cells that express TYR, TYRP1, MYRIP, Cadherin 1 or Cadherin 3 and TRPMI 1 or TRPMI 3, thereby producing human RPE cells.
US Pat. No. 10,479,776

PROCESS FOR THE PREPARATION OF EFINACONAZOLE

LUPIN LIMITED, Mumbai (I...

1. An improved process for the preparation of Efinaconazole or pharmaceutically acceptable salts thereof comprises reacting (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1H-1,2,4-triazol-1-yl)methyl]oxirane with 4-methylenepiperidine or its acid addition salt in the presence of an alkali or an alkaline earth metal halide.
US Pat. No. 10,480,032

USE OF EI24 GENE

University-Industry Found...

1. A method of diagnosing and treating EGFR-TKI drug resistance in an EGFR-TKI drug-administered patient, the method comprising:contacting a biological sample from an EGFR-TKI drug-administered patient with an antibody specifically binding to an EI24 protein and an antibody specifically binding to an insulin growth factor-1 (IGF-1) protein and detecting an expression level of the EI24 protein and the IGF-1 protein in the biological sample by detecting the antibody binding to the EI24 protein and to the IGF-1 protein;
diagnosing the EGFR-TKI drug-administered patient as having EGFR-TKI drug resistance when the expression level of the EI24 protein is 5 times to 20 times lower than that of a control sample obtained from an EGFR-TKI drug resistance-free control group and the expression level of the IGF-1 protein is greater than that of a control sample obtained from an EGFR-TKI drug resistance-free control group; and
administering an effective amount of EI24 and at least one selected from the group consisting of EGFR-TKI and an insulin growth factor-1 receptor (IGF-1R) inhibitor to the patient diagnosed as having EGFR-TKI drug resistance.
US Pat. No. 10,478,497

COMBINATIONS OF INECALCITOL WITH AN ANTI-CD38 AGENT AND THEIR USES FOR TREATING CANCER

HYBRIGENICS S.A., Paris ...

1. The combination of inecalcitol with an anti-CD38 agent, wherein said anti-CD38 agent is selected from the group consisting of daratumumab, isatuximab, and MOR202.
US Pat. No. 10,478,498

EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS

REFORM BIOLOGICS, LLC, W...

1. An injectable, liquid pharmaceutical formulation comprising at least about 100 mg/ml therapeutic protein and a viscosity-reducing amount of caffeine, wherein the viscosity-reducing amount of caffeine is about 15 mg/ml or less, and wherein the formulation further comprises niacinamide, andwherein the viscosity of the formulation is at least about 30% less than the viscosity of a control formulation, wherein the control formulation does not contain caffeine but is otherwise identical on a dry weight basis to the liquid pharmaceutical formulation.
US Pat. No. 10,480,036

METHODS OF DETECTING INFLUENZA

Cepheid, Sunnyvale, CA (...

1. A kit for detecting the presence of influenza in a sample from a human subject comprising(a) first primer pair for detecting an influenza A PA gene, wherein the first primer pair comprises a first and second primer, wherein
the first primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 20; and the second primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 21;
(b) a second primer pair for detecting an influenza A PB2 gene, wherein the second primer pair comprises a third and fourth primer, wherein
the third primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 17, and the fourth primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 18;
(c) a third primer pair for detecting an influenza A MP gene, wherein the third primer pair comprises a fifth and sixth primer, wherein
the fifth primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 23, and the sixth primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 24;
(d) a fourth primer pair for detecting an avian influenza MP gene, wherein the fourth primer pair comprises a seventh and eighth primer, wherein
the seventh primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 26, and the eighth primer comprises a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 27; and
(e) at least one probe selected from an influenza A PA probe comprising a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 22, an influenza A PB2 probe comprising a sequence that is at least 90% identical or complementary to at least 15 contiguous nucleotides of SEQ ID NO: 19, an influenza A MP probe comprising a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 25, and an avian influenza MP probe comprising a sequence that is at least 90% identical to at least 15 contiguous nucleotides of SEQ ID NO: 28.
US Pat. No. 10,478,499

ENGINEERED LIGHT-ACTIVATED ANION CHANNEL PROTEINS AND METHODS OF USE THEREOF

The Board of the Trustees...

1. A light-activated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:23, wherein the polypeptide functions as a light-activated anion channel, and wherein the polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions selected from A59S, E90S, E101S, E123S, Q117K, H134R, V242K, T246N and N258Q, relative to the amino acid sequence of ChR2 (SEQ ID NO:79).
US Pat. No. 10,478,500

COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION

Alnylam Pharmaceuticals, ...

1. A double stranded RNAi agent capable of inhibiting expression of HAO1 in a cell, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand nucleotide sequence consists of SEQ ID NO:589 and the antisense strand nucleotide sequence consists of SEQ ID NO:706;wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, and
wherein said sense strand is conjugated to a ligand attached at the 3?-terminus.
US Pat. No. 10,480,038

SYSTEM AND METHOD FOR PRODUCING A SUGAR STREAM

Fluid Quip Technologies, ...

1. A method for producing a sugar stream comprising:mixing ground grain particles with a liquid to provide a slurry;
separating the slurry into an initial solids portion and an initial liquid portion,
subjecting the initial solids portion to liquefaction to provide a first liquefied starch solution including starch and the initial solids and subjecting at least a portion of the initial liquid portion to a separate liquefaction step to provide a second liquefied starch solution including starch;
thereafter, subjecting the second liquefied starch solution to saccharification to convert the starch to simple sugars and produce a saccharified stream including the simple sugars; and
after saccharification of the second liquefied starch solution but prior to further processing of the simple sugars, separating the saccharified stream into a solids portion and a liquid portion including the simple sugars,
wherein, prior to separating the saccharified stream into the solids portion and the liquid portion, the separated initial solids remain separate from the saccharified stream of the second liquefied starch solution and wherein the separated liquid portion from the saccharified stream defines a sugar stream having a dextrose equivalent of at least 20 DE and a total unfermentable solids fraction that is less than or equal to 30% of a total solids content.
US Pat. No. 10,478,501

METHOD OF TREATING DISORDERS USING A PHARMACEUTICAL COMPOSITION OF OLIGOPEPTIDES

Merck Patent GmbH, Darms...

1. A method for the treatment of cancer wherein said cancer expresses ?v?3 and/or ?v?5 integrins, comprising a step of subcutaneously and/or intramuscularly administering to a patient who has been identified as having a cancer which expresses ?v?3 and/or ?v?5 integrins an effective amount of a composition which is a suspension comprising:a) 12 to 90% of the oligopeptide cyclo-(Arg-Gly-Asp-DPhe-NMeVal) having a solubility in water at 20° C. between 3 mg/ml and 10 mg/ml,
b) 0.01 to 60% of one or more lipophilic and/or amphiphilic compounds having a molar weight in the range of 200 g/mol to 2000 g/mol, and optionally
c) 0 to 87.99% of water, with the proviso that the sum of a), b) and c) sums up to 80 or more percent of the total composition with the proviso that said suspension composition contains 100 mg/ml or more of said oligopeptide, and with the further proviso that said suspension composition comprises 40% or more of said oligopeptide as solid particles.
US Pat. No. 10,478,502

PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION

Dow Pharmaceutical Scienc...

1. A pharmaceutical composition for topical application to the skin of an individual comprising:a liquid oil component comprising diethyl sebacate and a corticosteroid selected from the group consisting of halobetasol propionate, clobetasol propionate, betamethasone dipropionate, diflorasone diacetate, and fluocinonide at a concentration less than 0.05%; and
an aqueous component comprising water;
wherein the composition is free of white petrolatum.
US Pat. No. 10,478,503

BRANCHED OLIGONUCLEOTIDES

UNIVERSITY OF MASSACHUSET...

1. A branched oligonucleotide compound, capable of mediating RNA silencing in a neuronal cell, comprising two or more nucleic acid sequences, wherein the nucleic acid sequences (N) are connected to one another by one or more moieties selected from a linker (L), a spacer (S) and optionally a branching point (B),wherein each nucleic acid sequence is double-stranded and comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand each have a 5? end and a 3? end, and wherein the sense strand and the antisense strand each comprises >80% chemically-modified nucleotides,
wherein the nucleotides at positions 1 and 2 from the 5? end of the sense and antisense strands are connected to adjacent nucleotides via phosphorothioate linkages,
wherein each antisense strand comprises at least 15 contiguous nucleotides, wherein each sense strand comprises at least 15 contiguous nucleotides and has complementarity to the antisense strand, and wherein the antisense strand has complementarity to a target mRNA in the neuronal cell, and
wherein the antisense strand is complementary to a target mRNA in a neuronal cell.
US Pat. No. 10,478,504

TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS

PURDUE PHARMA L.P., Stam...

1. A solid oral dosage form comprisinga heat-labile gelling agent;
a thermal stabilizer comprising an anionic polymer in a neutral pH aqueous solution; and
a drug susceptible to abuse,
wherein the solid oral dosage form releases at least about 85% of the drug susceptible to abuse within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C.
US Pat. No. 10,478,505

EDIBLE OILS TO ENHANCE DELIVERY OF ORALLY ADMINISTERED STEROIDS

THE REGENTS OF THE UNIVER...

1. A method of treating, reducing, and/or mitigating a seizure caused by epilepsy, in a subject in need thereof, comprising administration to the subject orally a therapeutic regimen comprising a composition comprising allopregnanolone formulated in an edible oil selected from the group consisting of canola oil, peanut oil, and mixtures thereof, wherein the composition does not comprise a surfactant, wherein the subject suffers from seizure clusters, and wherein the allopregnanolone is administered at a dose from about 50 mg/kg to about 250 mg/kg.
US Pat. No. 10,480,043

SEAMLESS STEEL PIPE FOR LINE PIPE AND METHOD FOR PRODUCING THE SAME

NIPPON STEEL CORPORATION,...

1. A seamless steel pipe for line pipe having a chemical composition consisting, by mass percent, ofC: 0.03 to 0.15%,
Si: 0.50% or less,
Mn: 1.0 to 2.0%,
P: 0.050% or less,
S: 0.005% or less,
Cr: 0.1 to 1.0%,
Al: 0.001 to 0.10%,
N: 0.01% or less,
Ni: 0.05 to 2.0%,
B: 0.0003 to 0.0015%,
Ca: 0.0002 to 0.0050%,
Mo: 0.10 to 0.50%,
Ti: 0.001 to 0.05%,
Cu: 0 to 2.0%,
Nb: 0 to 0.05%,
V: 0 to 0.10%,
the balance: Fe and impurities, and
satisfying the following formula (i),
wherein a metal micro-structure of the steel pipe contains 50% or more of bainite, in an area fraction;
a wall thickness of the steel pipe is 25 mm or larger; and
in a scale formed on the surface of the steel pipe, metal particles consisting mainly of Ni or Cu having an average circle-equivalent diameter of 0.1 to 5 ?m exist, and a distance from a boundary between the base metal of the steel pipe and the scale to a region in which the metal particles do not exist is 20 ?m or longer:
2Nb+4V+Mo?0.50  (i)
where each symbol of element in formula (i) represents the content (mass %) of each element.
US Pat. No. 10,480,045

SELECTIVE REGENERATION OF ISOTOPE-SPECIFIC MEDIA RESINS IN SYSTEMS FOR SEPARATION OF RADIOACTIVE ISOTOPES FROM LIQUID WASTE MATERIALS

Kurion, Inc., Irvine, CA...

1. A method of treating radioactive waste, comprising:obtaining an ion exchange media, including one or more radioactive isotopes retained therein;
washing the ion exchange media with a selective regenerant agent to produce a wash solution comprising at least one radioactive isotope of the one or more radioactive isotopes;
mixing the wash solution comprising the at least one radioactive isotope with an isotope specific media to selectively extract at least some of the at least one radioactive isotope, wherein the at least some of the at least one radioactive isotope is retained within the isotope specific media; and
separating the isotope specific media retaining the at least some of the at least one radioactive isotope from the wash solution resulting in a treated wash solution.
US Pat. No. 10,481,072

NUCLEATED RED BLOOD CELL ANALYSIS SYSTEM AND METHOD

Abbott Laboratories, Abb...

1. A hematology analyzer for conducting a nucleated red blood cell (nRBC) analysis on a blood sample that contains a plurality of nRBCs, the analyzer comprising:an excitation source positioned to excite particles within the blood sample;
a detector unit comprising a fluorescence detector positioned to measure fluorescence emitted from the excited blood sample; and
a processor
a non-transitory computer-readable memory medium comprising instructions that cause the processor to:
excite the blood sample with the excitation source in a flow cell;
collect a plurality of fluorescence emission signals from the excited sample; and
prior to performing an nRBC differential analysis, exclude nuclei-free events and retain nuclei-containing events using only a fluorescence trigger that is limited to fluorescence emission signals and is set to a fluorescence magnitude that is greater than fluorescence emission signals from RBCs, including RBC fragments, and is less than fluorescence emission signals from white blood cells (WBCs) and nRBCs; and
perform the nRBC differential analysis on the nuclei-containing events.
US Pat. No. 10,478,511

THERAPEUTIC AGENT FOR TAUOPATHY AND METHOD FOR SCREENING THEREOF

National Center for Geria...

1. A method for inhibiting aggregation of tau proteins in Drosophila expressing human tau protein in neurons, comprising contacting the tau proteins with a fluorone dye or a pharmaceutically acceptable salt thereof, wherein aggregation of tau proteins is less in the presence of a fluorone dye as compared to tau aggregation in the absence of a fluorone dye.
US Pat. No. 10,480,049

COPPER ALLOY AND ITS USES

WIELAND-WERKE AG, Ulm (D...

1. A copper alloy consisting of the following composition in % by weight:from 10.6 to 18% of Al,
from 10.5 to 14.5% of Ni,
optionally up to 2% of Fe,
optionally up to 1% of Co,
optionally up to 0.5% of Ti,
optionally up to 0.5% of Mn,
optionally up to 0.15% of B,
optionally up to 0.1% of Ca, and
optionally up to 0.1% of C, with
the balance being copper,
characterized in that nickel aluminides of the NiAl type are embedded as precipitates in the microstructure of the alloy.
US Pat. No. 10,480,050

TITANIUM SHEET AND METHOD FOR PRODUCING THE SAME

NIPPON STEEL CORPORATION,...

1. A titanium sheet having a chemical composition containing, in mass %:Cu: 0.1 to 1.0%;
Ni: 0.10 to 0.20%;
Fe: 0.01 to 0.10%;
0: 0.01 to 0.10%;
Cr: 0 to 0.20%; and
the balance: Ti and unavoidable impurities, and
satisfying 0.04?0.3Cu+Ni?0.44%, wherein
an average grain size of a phase is 15 ?m or larger, and
an intermetallic compound of Cu and/or Ni, and Ti is at 2.0 volume % or less.
US Pat. No. 10,478,259

MEDICAL DEVICE PACKAGING WITH POWER SOURCE

BOSTON SCIENTIFIC SCIMED,...

1. A system for charging an onboard battery of a medical device prior to use of the medical device, the system comprising:a package defining a first cavity and a second cavity spaced apart from the first cavity;
a medical device disposed within the first cavity of the package, the medical device including an onboard rechargeable battery disposed within the medical device; and
a power source disposed within the second cavity of the package and capable of charging the onboard battery of the medical device prior to use of the medical device;
a controller disposed within the package and configured to use power stored within the power source to charge the onboard rechargeable battery disposed within the medical device prior to use of the medical device, the controller further configured to periodically check a power level within the onboard rechargeable battery and to recharge the onboard rechargeable battery when the power level of the onboard rechargeable battery drops below a threshold in order to maintain the medical device in a ready to use condition;
the system capable of being subjected to a sterilization process with the power source disposed within the second cavity.
US Pat. No. 10,480,054

COILED TUBE WITH VARYING MECHANICAL PROPERTIES FOR SUPERIOR PERFORMANCE AND METHODS TO PRODUCE THE SAME BY A CONTINUOUS HEAT TREATMENT

TENARIS COILED TUBES, LLC...

1. A method of heat treating a coiled tube, the method comprising:welding a plurality of steel strips together end to end to form a plurality of welded strips and longitudinally welding the plurality of strips to form a tube with a substantially constant inner diameter, outer diameter, and wall thickness along at least a first portion, a second portion and a third portion, the third portion being disposed between the first portion and the second portion:
coiling the tube on a spool to form the coiled tube;
uncoiling the coiled tube from the spool to obtain an uncoiled tube with the at least a first portion, the second portion and the third portion
selecting at least one predetermined parameter to be varied during a continuous quench and temper heat treatment process;
after uncoiling the coiled tube, performing the continuous quench and temper heat treatment process along the first portion, the second portion and the third portion, wherein the at least one predetermined parameter of the continuous heat treatment process applied to the first portion varies from the at least one predetermined parameter applied during the continuous heat treatment process to the third portion and the at least one predetermined parameter of the continuous heat treatment process applied to the third portion varies from the at least one predetermined parameter of the continuous heat treatment process applied to the second portion to thereby modify a microstructure of the uncoiled tube and thereby resulting in a composite uncoiled tube with the first portion having a greater post-heat-treatment yield strength value than a post-heat-treatment yield strength value of the third portion and the third portion having a greater post-heat-treatment yield strength value than a yield strength value of the second portion, and wherein the composite uncoiled tube after the continuous heat treatment process has a tempered martensite microstructure in the first, second and third portions of the uncoiled tube; and
re-coiling the composite uncoiled tube after performing the continuous quench and temper heat treatment process;
wherein the post-heat-treatment yield strength values are between 80 and 140 ksi.
US Pat. No. 10,479,799

SOLID CATALYST FOR DEHYDRATION OF MANNITOL, AND METHOD FOR PRODUCING 2, 5-SORBITAN AND/OR ISOMANNIDE USING THIS CATALYST

NATIONAL UNIVERSITY CORPO...

1. A solid, dehydration catalyst for producing 2,5-sorbitan and/or isomannide from mannitol comprising an H-type ? zeolite and/or a Y-type zeolite.
US Pat. No. 10,478,525

PROCESS FOR DEMINERALIZATION OF BONE MATRIX WITH PRESERVATION OF NATURAL GROWTH FACTORS

BACTERIN INTERNATIONAL, I...

1. A method for producing a three dimensional matrix, comprising:seeding a demineralized bone matrix with cells to form the three dimensional matrix, wherein the demineralized bone matrix was produced by a method comprising:
placing a bone body in a first processing solution comprising an acid to demineralize the bone body, wherein the demineralized bone body comprises bone fragments with at least one dimension greater than 2 mm;
periodically removing the bone body from the first processing solution to perform at least one test on a mechanical property of the bone body; and
exposing the bone body to a second processing solution when the test yields a desired result to produce a demineralized bone matrix, wherein the demineralized bone matrix comprises less than 2% residual calcium, wherein the test comprises a compression test on the bone body, wherein the compression test comprises applying a compressive force in a range from about 10 g-force/cm2 to about 4000 g-force/cm2 until the bone body uniformly compresses to less than about 60 percent of its original shape; or wherein the test comprises a bending test, wherein the bending test comprises applying a bending force in a range from about 10 g-force/cm2 to about 4000 g-force/cm2.
US Pat. No. 10,478,782

COMPOSITE HOLLOW FIBER MEMBRANE AND METHOD FOR PRODUCING SAME

TORAY INDUSTRIES, INC., ...

1. A composite hollow fiber membrane comprising at least a layer (A) and a layer (B), wherein:the composite hollow fiber membrane has an outer diameter of 20 to 350 ?m and an inner diameter of 14 to 250 ?m,
a tensile modulus of the composite hollow fiber membrane is from 1,000 to 6,500 MPa, the layer (A) contains a cellulose ester,
a thickness of the layer (A) is from 0.01 to 5 ?m, and
an open pore ratio HA of the layer (A) and an open pore ratio HB of the layer (B) satisfy HA
US Pat. No. 10,478,528

BONE GRAFT IMPLANTS CONTAINING ALLOGRAFT

PROSIDYAN, INC., Warren,...

1. A porous, composite bone graft implant comprising:a first component comprising a bioactive glass material in the form of a plurality of bioactive glass clusters, each cluster comprising a matrix of randomly oriented bioactive glass fibers and bioactive glass granules, at least some of the fibers and granules being sintered together, the clusters further including a bioactive glass shell at least partially encasing the matrix;
a second component comprising an allograft material, the second component being interspersed with the first component throughout the composite bone graft implant; and
a third component comprising a polymeric coating extending over the implant;
wherein the composite implant comprises a pore size distribution including at least a nanoporosity, and wherein the composite implant is pliable.
US Pat. No. 10,479,810

CRYSTAL FORM OF TENOFOVIR ALAFENAMIDE SALT, PREPARATION METHOD AND USE THEREOF

SHANGHAI BEGREAT PHARMATE...

1. A crystalline form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine fumarate designated as crystalline form A, having an X-ray powder diffraction pattern comprising diffraction peaks at at least one 2? value of: 23.8±0.2, 10.5±0.2, 28.5±0.2, 21.2±0.2, or 19.5±0.2.
US Pat. No. 10,478,531

METHODS AND MATERIALS FOR TREATING BLOOD VESSELS

1. An angioplasty balloon catheter comprising a stent-less angioplasty balloon coated with an amnion tissue preparation.
US Pat. No. 10,479,814

ADENOSINE RECEPTOR ACTIVATION REAGENT AND THE USES OF THEREOF

Zhejiang Subtropical Crop...

1. A method for treating a condition comprising administering N(6)-(2-hydroxyethyl)-adenosine (HEA) to a subject, wherein the condition is convulsion, pain, apoplexia, Parkinson's disease, or opioid drug addiction receptor; said HEA is administered in the amount of 10-15 mg/kg of subject body weight and treats the condition via the adenosine A1 receptor.
US Pat. No. 10,479,816

DECOY PEPTIDES INHIBITING PROTEIN PHOSPHATASE 1-MEDICATED DEPHOSPHORYLATION OF PHOSPHOLAMBAN

BETHPHAGEN INC., Gwangju...

1. A method for treating a disease associated with phospholamban (PLB) selected from the group consisting of heart failure, congestive heart failure, and ischemia, the method comprising administering to a subject in need thereof,(a) a pharmaceutically effective amount of a decoy peptide consisting of the peptide sequence represented by the following Formula I:
X1-Ala-X2-X3-Ile-Glu-X4  (1)
wherein X1 represents 0-1 amino acid residue(s), X2 represents Ser, Glu, or Asp, X3 represents Thr, Glu, or Asp and X4 represents 0-3 amino acid residue(s), with the proviso that X2 is not Ser when X3 is Thr;
wherein the decoy peptide inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation of PLB by competitive inhibition, wherein neither X1 nor X4 comprise membrane-spanning domains and X1 is not Tyr, and wherein the decoy peptide is linked to a cell membrane-permeable peptide;
and (b) a pharmaceutically acceptable carrier.
US Pat. No. 10,479,817

TEMPLATES FOR CONTROLLING SYNTHESIS OF NANOPARTICLES INTO DISCRETE ASSEMBLIES

1. A nanostructure comprising: (a) a conjugate molecule comprising a biomineralization peptide attached chemically at its N-terminus to a self-associating moiety, wherein the self-associating moiety is selected from a linear aliphatic carbon chain and an aromatic organic group; and (b) a nanoparticle comprising a metal or semiconductor element; wherein the biomineralization peptide binds to the metal or semiconductor element of the nanoparticle.
US Pat. No. 10,479,818

IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has glioblastoma, comprising administering to the patient a composition comprising a population of activated T cells that kill the cancer cells that present a peptide consisting of the amino acid sequence SLYKGLLSV (SEQ ID NO: 56),wherein the activated T cells are produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with a human class I or II MHC molecule on the surface of the antigen presenting cell.